UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, DC 20549

 FORM 10-K/A
 Amendment No. 1

 (Mark One)
 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the year ended December 31, 2024
 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from to
 Commission File Number 001-36362

 BioLife Solutions, Inc.
 (Exact name of registrant as specified in its charter)

 Delaware
 94-3076866

 (State or other jurisdiction of
incorporation or organization)
 (IRS Employer
Identification No.)

 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021
 (Address of registrant's principal executive offices, Zip Code)
 ( 425) 402-1400
 (Telephone number, including area code)
 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class
 Trading symbol
 Name of exchange on which registered

 Common stock, par value $0.001 per share

 BLFS
 The NASDAQ Stock Market, LLC

 Securities registered pursuant to Section 12(g) of the Act: None
 Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No o
 Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No o
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such said files). Yes No o

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
 Large accelerated filer Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging Growth Company o
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). o
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No
 As of the registrant's most recently completed second fiscal quarter, the aggregate market value of common equity (based on closing price on June 28, 2024 of $21.43 per share) held by non-affiliates was approximately $ 784 million.
 As of March 27, 2025, 47.5 million shares of the registrant's common stock were outstanding.
 EXPLANATORY NOTE
 This Amendment No. 1 on Form 10-K/A (this "Amendment No. 1") amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Annual Report"), originally filed by BioLife Solutions, Inc. with the Securities and Exchange Commission (the "SEC") on March 3, 2025. References throughout this Amendment No. 1 to "BioLife Solutions, Inc.", "BioLife", "we", "us", "our", or the "Company" refer to BioLife Solutions, Inc. and its subsidiaries, taken as a whole, unless the context otherwise indicates.
 We are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement for our 2025 Annual Meeting of stockholders (the "Annual Meeting") within 120 days of the end of our fiscal year ended December 31, 2024. Accordingly, this Amendment No. 1 is being filed solely to:

 • amend and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions, and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2024 Annual Report, in their entirety as set forth herein; and
 • file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item 15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
 Because no financial statements have been included in this Amendment No. 1, and because this Amendment No. 1 does not contain or amend any disclosure with respect to paragraphs 3, 4 and 5 of Items 307 and 308 of Regulation S-K, the corresponding certifications have been omitted. We are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, as no financial statements are being filed with this Amendment No. 1.
 Except as set forth above, no other Items of our 2024 Annual Report have been amended or revised in this Amendment No. 1, and all such other Items shall be as set forth in such 2024 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2024 Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have the meanings given to them in the 2024 Annual Report.

 Page No.

 ITEM 10.

 DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 ITEM 11.

 EXECUTIVE COMPENSATION

 ITEM 12.

 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 ITEM 13.

 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

 ITEM 14.

 PRINCIPAL ACCOUNTING FEES AND SERVICES

 ITEM 15.

 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 SIGNATURES

 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 The following table and text set forth the names and ages of our directors and executive officers as of March 27, 2025. Our Board of Directors (the "Board") is comprised of only one class of directors. Also provided herein are brief descriptions of the business experience of each director and executive officer during the past five years (based on information supplied by them) and an indication of directorships held by each director in other public companies subject to the reporting requirements under the federal securities laws. There are no legal proceedings related to any of the directors or executive officers that must be disclosed pursuant to Item 401(f) of Regulation S-K. There are no family relationships among any of our directors or executive officers. No director or executive officer has any arrangement or understanding between him or her and any other person(s) pursuant to which he or she is to be selected as a director or officer of the Company.

 Name
 Age
 Position and Offices With the Company

 Chief Executive Officer and Chairman of the Board

 Chief Financial Officer

 Aby J. Mathew, Ph. D.
 Chief Scientific Officer and Executive Vice President

 Chief Marketing Officer

 Chief Quality and Operations Officer

 Sean Werner
 Chief Technology Officer

 Sarah Aebersold
 Chief Human Resources Officer

 Cathy Coste(1)

 Amy DuRoss
 Lead Director

 Joydeep Goswami

 Tony Hunt(2)

 Tim Moore

 (1) Effective March 18, 2025, the Board appointed Cathy Coste to the Board and as a member and Chair of the Audit Committee.
 (2) Effective January 2, 2025, the Board appointed Tony J. Hunt to the Board and as a member of the Audit Committee. He was also appointed as a member of the Compensation Committee as of March 18, 2025.

 As of the date of the Company's 2024 Annual Meeting of Stockholders on August 1, 2024, a Joseph Schick, former member of the Board and Chair of the Audit Committee, stepped down from his Board position.
 Roderick de Greef has been Chief Executive Officer and Chairman of the Board since October 2023 at BioLife. Previously, Mr. de Greef began serving as a director of the Board in January 2023, prior to which he served as President and Chief Operating Officer from November 2021 until he retired on January 3, 2023. Mr. de Greef was appointed Chief Operating Officer from December 2019 to May 2021 after his appointment as Chief Financial Officer from May 2016 to November 2021. He also served as interim Chief Financial Officer and interim Secretary from March 2016 through May 2016. Mr. de Greef served as a director of the Company from June 2000 through November 2013 and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since November 2022, Mr. de Greef has served as a director of the Upper Connecticut Valley Hospital, a non-profit, rural hospital in northern New Hampshire. Since December 2020, Mr. de Greef has served as a director of Sirona Medical Technologies, a cardia electrophysiology company. From February 2019 to January 2021, Mr. de Greef served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation, a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of NASDAQ listed Cardiac Science, Inc., which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. Mr. de Greef received his Master of Business Administration degree from the University of Oregon, and a Bachelor of Arts in Economics and International Relations from San Francisco State University. Mr. de Greef has extensive experience in corporate finance and the business world in general as well as serving as an officer and director of public companies.
 Troy Wichterman has been Chief Financial Officer since November 2021. Before his appointment as Chief Financial Officer, Mr. Wichterman served as the Company's Vice President, Finance since November 2019. In that role, Mr. Wichterman oversaw the finance and accounting organization in the areas of integrating acquired businesses, acquisition due diligence and deal structure, SEC reporting, financial planning and analysis, operational finance, and audit compliance. Mr. Wichterman also served as Director of Financial Planning and Analysis from June 2016 to November 2019 and Financial Analyst from February 2015 to June 2016. Prior to joining the Company, he was most recently a Senior Financial Analyst, Acquisitions at Ventas, a public healthcare REIT, from January 2013 to September 2014. Prior to Ventas, he was most recently a Senior Portfolio Analyst at Heitman, a private equity REIT, from June 2009 – January 2013 and began his career as an Auditing Associate at PwC in Chicago from 2008 to 2009. Mr. Wichterman is a CPA (inactive) and holds a Bachelor of Business Administration degree and a Master of Accountancy degree from the University of Wisconsin – Madison.
 Aby J. Mathew, Ph. D. has been Executive Vice President and Chief Scientific Officer since December 2019. Before his appointment as Executive Vice President and Chief Scientific Officer, Dr. Mathew had served as Chief Technology Officer. Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and has been employed by BioLife since 2000. Dr. Mathew is a co-developer of BioLife's biopreservation media solutions and co-inventor on issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph. D. in Biological Sciences from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife's current commercial HypoThermosol and CryoStor product platforms and intellectual property foundation. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of, the Board of Directors, and Advisory Panel, of the Parent's Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the Board of Directors of PanTHERA CryoSolutions, Inc., the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, the Business Advisory Board of RoosterBio Inc., and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification.

 Todd Berard has been Chief Marketing Officer since December 2019. Before his appointment as Chief Marketing Officer, Mr. Berard had served as Vice President of Marketing since February 2015 and Senior Director of Marketing since July 2014. Previous to BioLife, Mr. Berard served as Director of Marketing at Verathon Medical; a division of Roper Inc., from September 2010 until July 2014, overseeing the global marketing, product development, and product launch strategies for a portfolio of six medical device brands. He also managed all strategic partnerships for product development and helped guide the organization through several key product launches and the corporate acquisition. At Verathon, Mr. Berard oversaw a creative and product management team of 12. Responsibilities included all global marketing initiatives and campaigns, strategy, product portfolio management, and strategic planning. He has over twenty years of experience in life sciences, health care, medical devices, and technology; working for both global leaders and small technology startups, including the University of Washington School of Medicine, DuPont, and Medtronic. He has a Bachelor of Science Degree in Biochemistry from the University of Vermont and an MBA from the University of Washington Foster School of Business.
 Karen Foster has been Chief Quality Officer since December 2019 and became Chief Quality and Operations Officer as of January 2024. Before her appointment as Chief Quality Officer, Ms. Foster had served as Vice President, Operations since April 2016. From 2003 to early 2016, Ms. Foster was Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank, and subsidiary of PerkinElmer Inc. Over a 25-year career, Ms. Foster has managed manufacturing and quality operations in several capacities for companies including ViaCord, Pfizer, Inc. (formerly Pharmacia Corporation) and Amersham Pharmacia Biotech, Inc. (formerly Phamacia Biotech, Inc.). She holds an MBA from the University of Wisconsin-Milwaukee (specialization in Operations Management), an M.S. in Zoology from University of Wisconsin-Milwaukee (specialization in Microbiology) and a B.S. in Biological Sciences from Michigan Technological University.

 Sean Werner has been Chief Technology Officer since November 2024. Prior to his appointment as Chief Technology Officer, Mr. Werner served as Senior Technology Officer, Life Sciences from September 2021 through November 2024. From October 2019 through September 2021, Mr. Werner was President of Sexton Biotechnologies, Inc, until its acquisition by the Company. Mr. Werner additionally served as Director of Regulatory Affairs of Cook Regentec LLC, a subsidiary of Cook Medical, Inc. ("Cook Medical"), from January 2015 through September of 2021. He also held the position of Director of Regulatory Science, Cell Therapies while at Cook Medical from October 2013 through October 2019. Mr. Werner has a combined 23 years of experience in various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. He has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools. Mr. Werner holds a BS in Biology from Indiana University, a PhD in Biology from Purdue University, and held post-doctoral positions at the Indiana University School of Medicine and Eli Lilly and Company.
 Sarah Aebersold has been Chief Human Resources Officer since January 2023. Previously, Ms. Aebersold was Vice President, Global Human Resources since January 2021 and served as the Senior Director, Global Human Resources & Administration since February 2020. In that role, Ms. Aebersold oversaw human resources programs in the areas of employee relations, talent acquisition, benefits, compensation, coaching, training and development, policy, and data management. Prior to joining the Company, Ms. Aebersold served in a variety of human resources roles with companies including MCG Health, a healthcare solutions provider (2016-2020, most recently as Head of Human Resources and Administration), Spacelabs Healthcare, a manufacturer of medical equipment (2014-2016, 2012-2013, most recently as Senior Manager, Human Resources), T-Mobile, a mobile communication company, (2013-2013, most recently as Human Resource Manager), Seattle Children's Hospital, a children's hospital (2009-2012, most recently as Manager, Human Resources Consulting), and ZymoGenetics, Inc., a biotechnology/pharmaceutical company (2004-2009, most recently as Human Resources Manager).

 Cathy Coste has served as a director and Chair of our Audit Committee since March 2025. Ms. Coste has served as a director of Biomerica, Inc. (NASDAQ: BMRA) since August 2020, Minerva Surgical, Inc. (which recently went private in 2024) since February 2021 and Renalytix plc (OTCQB: RNLXY) since June 2023, serving as audit committee chair for each. After over 32 years with Deloitte & Touche LLP ("Deloitte"), Ms. Coste retired from Deloitte in September 2020, where she most recently was a senior partner and life sciences industry executive leader. During her time with Deloitte, she served in corporate and professional services positions, ultimately leading global finance, internal audit and operations teams while participating in more than 200 audit committee meetings. Previously she worked at Mervyn's from April 1991 to February 1999, where she held positions of increased responsibility in accounting, financial planning and analysis, store facilities, and store operations. She holds a B.A. in Business Administration - Accounting from California State University, Hayward, and completed Harvard Business School's Corporate Director's Certificate Program. She is a licensed Certified Public Accountant. The Board has determined that Ms. Coste is qualified to serve as a director because of her expertise in financial services, audits, risk and controls, and compliance, and her decades of experience in the life sciences industry.

 Amy DuRoss has served as Lead Director of our Board of Directors since August 2023 and member of our Governance and Nominating Committee and as Chair of the Compensation Committee since April 2021. Ms. DuRoss previously served as Chief Executive Officer of Vineti, Inc., a healthcare technology company, from the time that she co-founded Vineti in April 2016 through March 2022. Ms. DuRoss led Vineti and its software as a service platform to the forefront of innovation supporting cell and gene therapy manufacturing, delivery and patient follow up. Before co-founding Vineti, Ms. DuRoss focused on healthcare new business creation for GE Ventures, a venture capital subsidiary of General Electric (NYSE: GE), serving as a Managing Director from May 2013 to May 2017. Prior to GE, Ms. DuRoss was Chief Business Officer at Navigenics, Inc., a genomics company sold to Life Technologies Corporation in 2012. Ms. DuRoss was Co-founder and Executive Director of Proposition 71, California's stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Ms. DuRoss was named a 2016 Health Innovator Fellow by the Aspen Institute. Ms. DuRoss also serves as a member of the Board of Directors for the ARM Foundation for Cell and Gene Medicine. Ms. DuRoss holds an MBA, Masters degree in English, and Bachelors of Arts degree in English from Stanford University. The Board has determined that Ms. DuRoss is qualified to serve as a director because of her experience founding and growing a successful business in the cell and gene therapy space.

 Rachel Ellingson has served as a director and member of our Compensation Committee and Audit Committee since April 2021. Since March 2025, Ms. Ellingson has served as Chief Strategy and Corporate Development Officer at Solventum, a diversified medical device company (NYSE: SOLV). As a member of the executive leadership team at SOLV, Ms. Ellingson is responsible for global oversight of strategy, business development, integration, and divestitures. Prior to her appointment at SOLV, Ms. Ellingson served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc., a medical device company focused in orthopedics (NYSE: ZBH) from April 2018 to March 2025. Ms. Ellingson also served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical, Inc., a medical device company focused on cardiovascular and neuromodulation therapies, from 2011 to 2017. Before joining St. Jude Medical, Ms. Ellingson served as Vice President, Business Development and Investor Relations at AGA Medical Corporation, a developer and manufacturer of cardiovascular medical devices. Ms. Ellingson was an investment banker prior to her appointment at AGA Medical, serving as a Managing Director in the Healthcare Investment Banking sector of Bank of America Corporation (NYSE: BAC) and prior to that, was with Cowen & Company (NASDAQ: COWN). Ms. Ellingson holds an MBA in Finance from the University of Connecticut and a Bachelor of Arts degree from the University of Rhode Island. The Board has determined that Ms. Ellingson is qualified to serve as a director because of her experience with strategic leadership and investment banking.

 Joydeep Goswami has served as a director, as a member of our Audit Committee and as Chair of our Nominating and Governance Committee since October 2021. Dr. Goswami served as Chair of our Audit Committee from August 2024 to March 2025. Dr. Goswami currently serves as President and Chief Executive Officer of LGC Group, an international life sciences measurement and tools company. Prior to his appointment as CEO of LGC Group in January 2025, Dr. Goswami served as an Advisor to Illumina, Inc. ("Illumina"), a life sciences tools and diagnostics company, between April 2024 to December 2024. From February 2023 and April 2024, Dr. Goswami also served as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina. During his service on the executive leadership team at Illumina, Dr. Goswami was responsible for driving planning, strategic partnerships, and acquisitions. Prior to Illumina, Dr. Goswami served as the President of the Clinical Next-Generation Sequencing (NGS) and Oncology business unit of Thermo Fisher Scientific Inc. ("Thermo Fischer Scientific"), where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Dr. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies Corp. ("Life Technologies") and Invitrogen Corp. ("Invitrogen"), in addition to Thermo Fisher Scientific. He has led teams across various functions, including sales, marketing, R&D and other support functions. Dr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies. Dr. Goswami holds his MS, PhD in Chemical Engineering, and MBA from MIT and a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology. The Board has determined that Dr. Goswami is qualified to serve as a director because of his experience with strategic and financial leadership and international operations experience.

 Tony J. Hunt has served as a director and member of our Audit Committee since January 2025, and a member of our Compensation Committee since March 2025. Mr. Hunt has served as Executive Chairman of Repligen Corporation, or Repligen (NASDAQ: RGEN), since September 2024. Prior to being named Executive Chairman of Repligen, Mr. Hunt served as Chief Executive Officer and as a member of the board of directors of Repligen since May 2015, having joined Repligen in May 2014 as Chief Operating Officer. Prior to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies Corporation, or Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008

 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and a M.B.A. from Boston University School of Management. The Board has determined that Mr. Hunt is qualified to serve as a director because of his deep understanding of the bioprocessing market and prior experience as a public company director.

 Tim Moore has served as a director and member of our Compensation and Nominating and Governance Committees since September 2022. He has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Mr. Moore served as Executive Vice President, Chief Technical Operations at Allogene Therapeutics, Inc. through February 2025, an allogeneic company for CAR-T cell therapy. Mr. Moore also served as COO of Instil Bio through December 2022, a TIL cell therapy company focused on solid tumors. Mr. Moore also served as the President and COO at PACT Pharma from October 2019 through September 2022. Prior to joining PACT, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia. Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech's Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University. The Board has determined that Mr. Moore is qualified to serve as a director because of his extensive experience with leading and executing large scale manufacturing operations in the biopharmaceutical industry.
 Except as otherwise provided by law, each director shall hold office until either their successor is elected and qualified, or until he or she sooner dies, resigns, is removed or becomes disqualified. Officers serve at the discretion of the Board.
 Board of Directors
 Overview
 Our Bylaws provide that the size of our Board is to be determined from time to time by resolution of the Board but shall consist of at least three members. Our Board currently consists of seven members. Mr. de Greef serves as Chairman of the Board and is Chief Executive Officer and Amy DuRoss serves as Lead Director of the Board.
 At each annual meeting of stockholders, members of our Board are elected to serve until the next annual meeting and until their successors are duly elected and qualified.
 Committees of the Board of Directors
 The Board has established an Audit Committee, a Compensation Committee, and a Governance and Nominating Committee. Each committee operates pursuant to a written charter that may be viewed on our website at  The inclusion of our web site address in this document does not include or incorporate by reference the information on our web site into this annual filing.

 The following table sets forth the current composition of the three standing committees of our Board:

 Name
 Board
 Audit
 Compensation
 Governance
and
Nominating

 Mr. de Greef
 Chair

 Ms. Coste
 X
 Chair

 Ms. DuRoss
 X
 Chair
 X

 Ms. Ellingson
 X
 X
 X

 Mr. Goswami
 X
 X
 Chair

 Mr. Hunt
 X
 X
 X

 Mr. Moore
 X
 X
 X

 Audit Committee. Our Audit Committee's role includes the oversight of our financial, accounting and reporting processes; our system of internal accounting and financial controls; and our compliance with related legal, regulatory, and ethical requirements. The Audit Committee oversees the appointment, compensation, engagement, retention, termination and services of our independent registered public accounting firm, including conducting a review of its independence; reviewing and approving the planned scope of our annual audit; overseeing our independent registered public accounting firm's audit work; reviewing and pre-approving any audit and non-audit services that may be performed by our independent registered public accounting firm; reviewing with management and our independent registered public accounting firm the adequacy of our internal financial and disclosure controls; reviewing our critical accounting policies and the application of accounting principles; and monitoring the rotation of partners of our independent registered public accounting firm on our audit engagement team as required by regulation.
 In addition, the Audit Committee's role includes meeting to review our annual audited financial statements and quarterly financial statements with management and our independent registered public accounting firm. The Audit Committee has the authority to obtain independent advice and assistance from internal or external legal, accounting and other advisors, at the Company's expense.
 The Board has determined that all members of our Audit Committee meet the independence and financial literacy standards of NASDAQ and applicable SEC rules. The Board has determined that Ms. Coste is an "audit committee financial expert" as defined by the rules of the SEC.
 Compensation Committee. The purpose of the Compensation Committee is to discharge its fiduciary responsibilities relating to the compensation of executive officers, the organizational structure, succession, retention and training policies and review and oversight of benefit programs. Our Compensation Committee is responsible for reviewing the recommendations of our Chief Executive Officer and Chief Financial Officer, making recommendations to the Board regarding the compensation of our executive officers, and ensuring that the total compensation paid to the executive officers is reasonable and competitive, and does not promote excessive risk taking. In making its recommendation to the Board, the Compensation Committee considers the results of the most recent stockholder advisory vote on executive compensation. The Chief Executive Officer may not be present during voting or deliberation on his compensation. The Compensation Committee is also responsible for reviewing and making recommendations to the Board regarding director and committee member compensation. In addition, the Compensation Committee approves and has oversight over our bonus plans for executive officers and/or stock-based compensation plans and oversight of our overall compensation plans and benefit programs, including approval and oversight of grants.
 In discharge of its duties related to administration of executive bonus plans, the Compensation Committee may, subject to the terms of each plan, delegate authority to management for the day-to-day non-material administration of such plans. Further, the Compensation Committee may, subject to the terms of each plan, delegate authority to management to make grants to non-executive officers under stock-based compensation plans.
 The Compensation Committee has the authority to obtain independent advice and assistance from internal or external legal, accounting and other advisors, at the Company's expense. The Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Committee, other than in-house legal counsel, only after taking into consideration the six factors outlined in Rule 10C-1 of the Exchange Act. In considering and determining

 compensation levels, the Compensation Committee reviews independent and externally generated compensation data, in accordance with Rule 10C-1 of the Exchange Act.
 The members of the Compensation Committee are independent directors under the applicable NASDAQ listing rules.
 Governance and Nominating Committee. Our Governance and Nominating Committee's primary purpose is to evaluate candidates for membership on our Board and make recommendations to our Board regarding candidates; make recommendations with respect to the composition of our Board and its committees; provide guidance to our human resources, legal, and finance departments relating to director orientation programs; recommend corporate governance principles applicable to the Company; manage periodic review, discussion and evaluation of the performance of our Board, its committees and its members and oversee and monitor compliance with our Code of Business Conduct and Ethics. The Governance and Nominating Committee has the authority to obtain independent advice and assistance from internal or external legal, accounting, and other advisors, at the Company's expense.
 All members of our Governance and Nominating Committee are independent are independent directors under the applicable NASDAQ listing rules.
 The Governance and Nominating Committee will consider candidates recommended by stockholders in accordance with the procedures set forth in our Bylaws, and prior to the date it recommends a slate of director nominees to the Board. Pursuant to the Governance and Nominating Committee Charter, there is no difference in the manner in which a nominee recommended by a stockholder or otherwise is evaluated.
 In carrying out its function to nominate candidates for election to our Board, the Governance and Nominating Committee considers the Board's mix of skills, experience, character, commitment and diversity, with diversity being broadly construed to mean a variety of opinions, perspectives and backgrounds, such as gender, race and ethnicity differences, as well as other differentiating characteristics, all in the context of the requirements and needs of our Board at that point in time. In reviewing potential candidates, the Committee will also consider all relationships between any proposed nominee and any of our stockholders, competitors, customers, suppliers or other persons with a relationship to the Company. The Governance and Nominating Committee believes that each candidate should be an individual who has demonstrated exceptional ability and judgment, who are willing and able to make a sufficient time commitment to the Company, and who shall be most effective, in conjunction with the other nominees to the Board, in collectively serving the long-term interests of the stockholders.
 The Governance and Nominating Committee's methods for identifying candidates for election to our Board include the solicitation of ideas for possible candidates from a number of sources, including from members of our Board, our executive officers, individuals who our executive officers or Board members believe would be aware of candidates who would add value to our Board and through other research. The Governance and Nominating Committee may, from time to time, retain, for a fee, one or more third-party search firms to identify suitable candidates. The Governance and Nominating Committee will consider all candidates identified through the processes described above, and will evaluate each candidate, including incumbents, based on the same criteria.
 The Governance and Nominating Committee does not have a formal policy with respect to diversity; however, the Board and the Governance and Nominating Committee believe that it is essential that the Board members represent diverse viewpoints.
 Stockholder Nominees for Director
 There have been no material changes to the procedures by which stockholders may recommend nominees to the Board.
 Codes of Business Conduct and Ethics
 We believe in sound corporate governance practices and have always encouraged our employees, including officers and directors to conduct business in an honest and ethical manner. Additionally, it has always been our policy to comply with all applicable laws and provide accurate and timely disclosure.
 Accordingly, the Board has adopted a Code of Business Conduct and Ethics for all employees. The Board has adopted an additional corporate code of ethics for its Chief Executive Officer, Chief Financial Officer, and other senior financial officers, which is intended to be a "code of ethics" as defined by applicable SEC rules. The Code of Business Conduct and

 Ethics is publicly available on our website at  The Code of Business Conduct and Ethics is designed to deter wrongdoing and promote honest and ethical conduct and compliance with applicable laws and regulations. These codes also incorporate what we expect from our executives so as to enable us to provide accurate and timely disclosure in our filings with the SEC and other public communications. Any amendments made to the Code of Business Conduct and Ethics will be available on our website.

 Delinquent Section 16(a) Reports
 Section 16(a) of the Exchange Act requires the Company's directors and executive officers, and persons who own more than 10% of a registered class of the Company's equity securities, to file with the SEC reports of beneficial ownership and reports of changes in beneficial ownership in the Company's securities. Based solely upon a review of Forms 3, 4 and 5, and amendments thereto, filed electronically with the SEC during the year ended December 31, 2024, the Company believes that all Section 16(a) filings applicable to its directors, officers, and 10% stockholders were filed on a timely basis during the year ended December 31, 2024, except those listed below:
 • March 13, 2024: Section 16(a) filing filed late by Amy DuRoss reflecting one late Form 4 reporting three transactions.
 • April 18, 2024: Section 16(a) filing filed late by Todd Berard reporting one late Form 4 reflecting one transaction.
 • April 23, 2024: Section 16(a) filing filed late by Sarah Aebersold, Todd Berard, Karen Foster, Aby J. Mathew, and Troy Wichterman. Each filed one late Form 4 reporting one transaction, with the exception of Sarah Aebersold, who reported two transactions.
 • September 18, 2024: Section 16(a) filings filed late by Sarah Aebersold, Todd Berard, Karen Foster, Aby J. Mathew, and Troy Wichterman. Each filed one late Form 4 reporting three transactions, with the exception of Sarah Aebersold, who reported four transactions.
 • December 19, 2024: Section 16(a) filing filed late by Aby J. Mathew reflecting one late Form 4 reporting two transactions.
 Insider Trading Policy
 We have adopted a formal insider trading policy that governs the purchase, sale, and/or disposition of our securities, as well as the securities of other companies with whom we have a business relationship, by directors, officers, employees, and consultants that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable listing standards. A copy of our insider trading policy was filed as Exhibit 19.1 to our 2024 Annual Report filed with the SEC on March 3, 2025. This policy has been designed to prevent insider trading or even allegations of insider trading.

 ITEM 11. EXECUTIVE COMPENSATION
 Compensation Committee Report
 Our Compensation Committee, which is comprised solely of independent directors within the meaning of applicable rules of NASDAQ and non-employee directors within the meaning of Rule 16b-3 under the Exchange Act, is responsible for developing executive compensation policies and advising the Board with respect to such policies and administering the Company's cash and equity incentive plans. Subject to Board approval, the Compensation Committee sets performance goals and objectives for the CEO and the other executive officers, evaluates their performance with respect to those goals and sets their compensation based upon the evaluation of their performance. In evaluating executive officer pay, the Compensation Committee may retain the services of a compensation consultant and consider recommendations from the CEO with respect to goals and compensation of the other executive officers. The Compensation Committee assesses the information it receives in accordance with its business judgment. The Compensation Committee also periodically reviews non-employee director compensation. All decisions with respect to executive compensation are generally recommended by the Compensation Committee to the full Board for approval and all decisions with respect to director compensation are recommended by the Compensation Committee to the full Board for approval.

 Our Compensation Committee has reviewed and discussed the compensation discussion and analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board that the compensation discussion and analysis be included in this document.
 Respectfully submitted by the Compensation Committee:
 Amy DuRoss, Chairperson
 Tony Hunt
 Timothy Moore
 Compensation discussion and analysis
 Our compensation discussion and analysis ("CD&A") describes our executive-compensation philosophy and program as reported in the executive compensation tables that follow, which provide information relating primarily to compensation decisions for the following 2024 named executive officers ("NEOs") of the Company:

 Name
 Position with the Company

 Chief Executive Officer and Chairman of the Board

 Chief Financial Officer

 Chief Scientific Officer and Executive Vice President

 Chief Marketing Officer

 Garrie Richardson(1)

 Former Chief Revenue Officer

 Chief Quality and Operations Officer

 (1) As of November 12, 2024, Garrie Richardson was terminated from his position as Chief Revenue Officer in connection with the divestiture of SciSafe, Inc. Mr. Richardson is included as an NEO pursuant to Regulation S-K.
 2024 year in review

 For the fiscal year ended December 31, 2024, we were able to successfully transition to a more streamlined, focused bioproduction products and services company servicing the cell and gene therapy market. We were able to accomplish three successful divestitures consisting of Global Cooling and Custom Biogenics (the "Freezer Business") and our storage business, SciSafe. This not only provided us with a significant influx of cash as of the year ended December 31, 2024, but also allows the Company to prioritize greater efficiencies in its proprietary cell processing products and services, deepen our relationships with existing biopreservation media customers, emphasize cross-selling of other cell processing products and services, and continue to optimize our long-term value to our customers and shareholders. Among our accomplishments in the year ended December 31, 2024 were the following:

 Revenue and other financial metric performance
 • Revenue increased to $82.3 million, an overall gain of 8% year -over-year, compared to revenue of $75.9 million in 2023
 • Sequential increase in cell processing revenue for each quarter of the year ended December 31, 2024
 • Positive adjusted EBITDA of $15.6 million, or 19% as a percentage of revenue (adjusted EBITDA is a non-GAAP metric; please see the Non-GAAP metric reconciliation table section below for a reconciliation of adjusted EBITDA to its most directly comparable GAAP financial measure)

 Business highlights
 • Divestitures of Global Cooling (April 2024), Custom Biogenics ("CBS") (November 2024), and SciSafe (November 2024) providing approximately $74.7 million in cash during the year ended December 31, 2024
 • Release of CellSeal CryoCase product

 In summary, we met our objectives set forth in the prior year to streamline our business to return the greatest value to our customers and shareholders. We are keenly focused on continuing this progress and strengthening our current product portfolio and market exposure for the best interest of the Company and our shareholders.

 Compensation philosophy
 The Company's compensation philosophy is to provide compensation that will attract and retain high-performing talent in our industry, motivate the Company's executive officers to create long-term, enhanced shareholder value and provide a fair reward for executive effort, and stimulate professional and personal growth. The Company believes that the compensation of its executive officers should align the executive officers' interests with those of the shareholders and focus executive officer behavior to achieve both near-term corporate goals and long-term business and strategies.
 It is the responsibility of our Compensation Committee to administer the Company's compensation programs to ensure that they are competitive with other bioprocessing, life sciences, and biotechnology companies, and to include incentives that are designed to appropriately drive the Company's continued development to create shareholder value. The Compensation Committee reviews and approves (and, where required, recommends to the Board for approval) all components of the Company's executive officer compensation, including base salaries, annual cash incentive compensation, and equity incentive compensation.
 Compensation objectives
 The Company's compensation programs for its executive officers are designed to provide the following:
 • Salaries and total compensation that are competitive with other bioprocessing, life sciences, and biotechnology companies with which the Company competes for talent, determined by comparing the Company's pay practices with these companies. The Compensation Committee's objective is to align executive total annual compensation, including salary, cash bonus and long-term equity, near the 50th percentile of the Company's peer group, although peer group benchmarking is only one of several factors the Compensation Committee considers.
 • Equity incentive compensation, including market-based equity awards, to ensure that its executive officers are motivated over the long-term to respond to the Company's business challenges and opportunities as owners and not just as employees, thereby aligning the executive officers' interests with those of shareholders.
 • Annual cash incentive compensation that motivates the executive officers to lead and manage the business to meet the Company's near-and long-term objectives.
 The following features of our compensation programs are designed to protect and promote the interests of our shareholders while aligning executive compensation with performance. Below we summarize practices we follow to incentivize performance and retain leadership, and practices we do not follow because we do not believe they serve the long-term interests of our shareholders:

 We Do
 We Don't

 Pay for Performance: We emphasize market-based compensation that aligns the interests of our shareholders and executive officers through the use of both near-term cash incentive compensation and long-term equity awards subject to both time and market-based vesting.

 Hedge or Pledge: We do not allow executive officers to engage in hedging or pledging of our securities.

 Benchmark: We maintain an industry-specific peer group for annual benchmarking of executive compensation. This benchmarking is a key factor among those used to determine appropriate compensation for our NEOs.

 Re-Pricing: We do not allow re-pricing of underwater stock options without shareholder approval.

 Benefits: We offer market-competitive benefits for executives that are consistent with the benefits we offer all our employees.

 Gross up Payments: We do not provide excise tax gross-up payments for our executive officers.

 Consult: We consistently engage an independent compensation consultant to advise on compensation levels and practices.

 Guaranteed Bonuses: We do not provide guaranteed bonuses to our executive officers.

 Risk Assessment: We perform an annual compensation risk assessment.

 Double Trigger: We provide each NEO severance benefits that are triggered only upon an involuntary termination of employment, including resignation for good reason, following a change-in-control (i.e., double trigger).

 Board and Compensation Committee consideration of shareholder advisory votes on compensation
 In evaluating our executive compensation programs for the fiscal year ended December 31, 2024, the Compensation Committee considered the shareholder advisory vote on our executive compensation, (the "say-on-pay vote"), for the fiscal year ended December 31, 2023, which was approved by 82.4% of the votes cast.
 The Compensation Committee determined that the structure of our executive compensation policies continues to be appropriately aligned to the achievement of Company goals and objectives and the best interests of shareholders. We believe that compensation program enhancements of the past several years, as well as our commitment to improved transparency in our CD&A disclosure, have resulted in a compensation program that best serves our Company, our executives, and our shareholders. The Compensation Committee values and continues to consider shareholder input and feedback, including the results of say-on-pay votes, on our compensation program structure.
 Compensation evaluation process
 The Company's executive officer compensation consists of three primary components: base salary, annual cash incentive compensation, and equity incentive compensation. Each of these components is intended to complement the others, and taken together, to satisfy the Company's compensation objectives. The Compensation Committee considers a number of factors in setting compensation for its executive officers, including Company performance, the executive's functional performance, experience and responsibilities, and the compensation of executive officers in similar positions in our peer group of companies.
 Role of management
 The Compensation Committee consults with our CEO and management when making compensation decisions to gather information on corporate and individual performance, the perspective of management, and their recommendations on compensation matters. The Compensation Committee uses these recommendations as one of several factors in making compensation decisions, and those decisions do not necessarily follow management's recommendations. While the CEO may make recommendations to the Compensation Committee regarding the pay of other executive officers, he is not present during deliberations related to his own compensation.
 Role of compensation consultant
 In establishing compensation levels for each executive officer, the Compensation Committee has the authority to engage the services of outside experts. For analysis of the fiscal year ended December 31, 2024 executive compensation structure, the Compensation Committee retained Frederic W. Cook & Co, Inc. ("FW Cook"), an independent compensation consulting firm, to assist management in assessing and reporting to the Compensation Committee the competitiveness and effectiveness of the Company's executive compensation programs. In addition, our finance and human resources departments support management in their work and act in accordance with the direction given to them to administer our compensation programs.
 The Compensation Committee has assessed any potential conflicts of interest raised by the work of FW Cook, our compensation consultant, pursuant to applicable SEC rules and NASDAQ listing rules and has determined that no such conflict of interest exists.
 In January 2024 the Compensation Committee held meetings with management to review the reports prepared by FW Cook to:
 • Review our compensation objectives
 • Review the actual compensation of our executive officers for consistency with our objectives
 • Analyze trends in executive compensation
 • Assess our variable cash compensation structure, as well as incentive plan components and mechanics, to ensure an appropriate correlation between pay and performance with resulting compensation opportunities that balance returns to the Company and its shareholders
 • Assess our equity-based awards programs against our objectives of executive incentive, retention, and alignment with shareholder interests
 • Review our peer group and consider appropriate changes related to the realignment of our business

 • Benchmark our executive cash compensation and equity-based awards programs, and assess our pay versus performance against our peer group
 • Review recommendations for fiscal year 2024 compensation for appropriateness relative to our compensation objectives
 Use of peer group to benchmark compensation
 In January 2024, FW Cook provided the Compensation Committee with an analysis of base salary, target bonus, target total cash, long-term incentive value and design, and target total compensation for executives, and cash and equity compensation for non-employee directors, of comparable companies in the bioprocessing, life sciences, and biotechnology industries. In performing this analysis, FW Cook used a peer group of 20 bioprocessing, life sciences, and biotechnology companies, which was reviewed and approved by management. As necessary, FW Cook, in conjunction with management, reevaluates our peer group in light of developments in the market and our industry. As a result of this review, the Compensation Committee determined to add three companies to the peer group and to remove three companies from the peer group compared to the prior report. The companies included in the peer group had revenues of approximately ranging from 50% to 900% of our revenue for the most recent year ended, which was December 31, 2023.
 The peer group used in the report presented for consideration of 2024 compensation decisions and approved by the Compensation Committee consisted of the following companies:

 ANGO
 AngioDynamics
 CDXS
 Codexis
 NVRO
 NEVRO Corporation

 AORT
 Artivion
 CYRX
 Cryoport
 MCRB
 Seres Therapeutics

 ATRI(1)

 Atrion Corporation
 GKOS
 Glaukos
 SILK(3)

 Silk Road Medical, Inc.

 CDMO
 Avid Bioservices
 IRTC
 iRhythm
 STAA
 STAAR Surgical Company

 AXGN
 Axogen Corporation
 MXCT
 MaxCyte
 LAB
 Standard BioTools

 AZTA
 Azenta
 MLAB
 Mesa Laboratories, Inc.
 VCYT
 Veracyte, Inc.

 CERS
 Cerus Corporation
 NSTG(2)

 Nanostring Technologies, Inc.

 (1)Atrion Corporation was acquired by Nordson Corporation (NASDAQ: NDSN) as of August 2024.
 (2)Nanostring Technologies, Inc. was acquired by Bruker Technologies (NASDAQ: BRKR) as of April 2024.
 (3)Silk Road Medical, Inc. was acquired by Boston Scientific Corporation (NASDAQ: BSX) as of September 2024.
 The use of peer group compensation data is one of several factors in determining appropriate compensation parameters for base salary, variable cash compensation, and equity-based, long-term incentives. The Compensation Committee's executive compensation decisions are made on a case-by-case basis, and specific benchmark results do not, in and of themselves, determine individual target compensation decisions.
 While the Compensation Committee generally targets each NEO's total compensation to be near the 50th percentile of the peer group, it considers a number of additional factors to determine the appropriate level of each NEO's total compensation and each component of compensation, including Company performance and the relevant executive's performance, experience, responsibilities and impact. Due to these other factors, the Compensation Committee may set an NEO's compensation below, at, or above the 50th percentile of the peer group.
 Annual review of long-term incentives
 The Compensation Committee believes that equity incentives in the form of restricted stock awards, subject to vesting over time or upon achievement of performance or market-based objectives, are effective vehicles to align individual and team performance with the achievement of the Company's strategic and financial goals over time, retain our NEOs, and align the interests of our NEOs with those of our shareholders.
 In March 2024, the Compensation Committee granted to the NEOs, service vesting-based restricted stock awards which vest over a four-year period, and market-based restricted stock awards which contain a market condition based on Total Shareholder Return ("TSR"). The TSR market condition measures the Company's performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31,

 2025 as compared to the total shareholder return of our 20 company peer group disclosed above. The size of these grants is based on target long-term incentive levels for each of the NEOs.

 Executive compensation

 Base salary

 Base salary represents the fixed portion of an executive officer's compensation and is intended to provide compensation for day-to-day performance. The Compensation Committee believes that a competitive base salary is a necessary element of any compensation program that is designed to attract and retain talented and experienced executives. Each executive officer's base salary is initially determined upon hire or promotion based on the executive officer's responsibilities, prior experience, individual compensation history and salary levels of other executives within the Company and similarly situated executives within our peer group. Base salary is typically reviewed annually. The Compensation Committee believes that the base salaries paid to our executive officers during the fiscal year ended December 31, 2024 achieved the Company's compensation objectives. Base salaries for the NEOs for 2024, 2023 and 2022 are as follows:

 Name
 2024 Base Salary ($) (1)
 2023 Base Salary ($) (1)
 Base Salary Increase in 2024 vs 2023 (%)

 Roderick de Greef(2)

 —

 —

 —

 Todd Berard(3)

 370,000
 332,000

 Garrie Richardson(4)

 367,500
 367,500
 —

 430,000
 382,000

 (1) These base salary increases were based on each NEO's performance, qualifications, experience, responsibilities, and FW Cook's survey of the publicly disclosed compensation for similar positions at companies in the peer group.
 (2) The 2023 base salary presented here is reflecting the annual salary as outlined within the employment agreement of Mr. de Greef. The actual salary earned by Mr. de Greef is presented within the Summary compensation table as he had not served in his position for the entirety of 2023.
 (3) The 2024 base salary presented here is reflecting the annual salary as outlined within the employment agreement of Mr. Berard. The actual salary earned by Mr. Berard is presented within the Summary compensation table as he received a salary increase during the year ended December 31, 2024.
 (4) The 2024 base salary presented here is reflecting the annual salary as outlined within the employment agreement of Mr. Richardson. The actual salary earned by Mr. Richardson is presented within the Summary compensation table as he had not served in his position for the entirety of 2024.
 Annual cash incentive compensation (short-term incentive) plan
 In 2024, as in prior years, executives were eligible for bonuses, as approved by the Compensation Committee and the Board, with pre-established goals and weightings, which was designed to reward achievements based upon quantitative and qualitative Company performance (the "Company Objectives"), and to incentivize and reward NEOs for achieving performance goals that drive Company performance, align pay and performance, and support the long-term growth of the Company.
 All NEO incentive payouts are calculated based solely on Company Objectives to closely align compensation with the Company's performance. The Compensation Committee determines each NEO's annual cash incentive compensation after the end of each fiscal year, which is calculated as a percentage of the executive officer's target annual cash incentive compensation ("Target Award"). The Compensation Committee establishes each NEOs Target Award at a level that represents a meaningful portion of each NEO's cash compensation. In addition, the Compensation Committee sets thresholds, target, and maximum performance goals, and related payout levels, considering annual cash incentive compensation levels for comparable positions within our peer group and our own historical practices. An NEO could earn between 0% and 118% of the NEOs Target Award for achievement of Corporate Objectives, dependent upon the level of achieved performance.

 Annual cash incentive compensation (short-term incentive) plan protocol
 The Compensation Committee administers the Plan:
 1.At the beginning of the fiscal year, the CEO, with assistance from senior management, proposes annual Company Objectives, measurement criteria and weightings, subject to review and approval by the Compensation Committee.
 2.At the beginning of the following fiscal year, the CEO and CFO evaluate performance levels and the achievement of these annual Company Objectives, which are subject to review and approval by the Compensation Committee. Specific bonus award recommendations for all participants are submitted by the CEO to the Compensation Committee for review and approval.
 3.The Compensation Committee determines the bonus awards for individual participants based on the Target Awards and the Company's performance against the Company Objectives.
 4.For determinations regarding executive officers, the Compensation Committee generally makes a recommendation to the Board for its approval.
 Summary of 2024 performance measure and goals
 The Compensation Committee may, at its discretion, elect to adjust bonuses or not to pay bonuses at all. A Target Award and the weight assigned to Company Objectives are determined based upon competitive market data derived from our peer group. The final incentive payout is determined based on the achievement of Company Objectives defined for each organizational level and position and the Target Award.
 Our Company is focused on driving above-industry level growth through internal innovation, acquisitions, and expansion of applications for our products and services. With our focus on revenue growth and positive adjusted EBITDA, we believe that revenue and adjusted EBITDA are relevant metrics to reflect success. Revenue and adjusted EBITDA held the highest weight of Company Objectives, and the remaining weighting was attributed to each of the other Company Objectives as recommended by management and approved by the Compensation Committee. We believe these are objectives that our executive team can directly impact, and that drive shareholder value.
 For the 2024 Plan, the Compensation Committee set the following Company Objectives and related payout levels:
 • Revenue (30%): For 2024, the revenue target was set at $76 million, which if achieved, would result in a payout of 30% of each NEOs Target Award. If the Company achieved revenues of $81 million, a 30% increase of payout would result and each NEOs Target Award would be paid at 39% with respect to the revenue metric. If achieved performance was below $76 million but at or above $71 million, a 30% reduction of payout would result and each NEOs Target Award would be paid at 21% with respect to the revenue metric. If achieved performance was below $71 million, then no payout would be made to the NEOs with respect to the revenue metric.
 • Adjusted EBITDA Margin(1) (30%): For 2024, the adjusted EBITDA target was set at 13% of revenues, which if achieved, would result in a payout of 30% of each NEOs Target Award with respect to the adjusted EBITDA metric. If the Company achieved adjusted EBITDA of 16% of revenues, a 30% increase of payout would result and each NEOs Target Award would be paid at 39% with respect to the adjusted EBITDA metric. If achieved performance was below 13% of revenues but at or above 10% of revenues, a 30% reduction of payout would result and each NEOs Target Award would be paid at 21% with respect to the adjusted EBITDA metric. If achieved performance was below 10% of revenues, then no payout would be made to the NEOs with respect to the adjusted EBITDA metric.
 • Remediation of material weaknesses (20%): In 2024, the objective to remediate material weaknesses, and incur no additional material weaknesses, would result in a payout of 20% of each NEOs Target Award. If all material weaknesses were not remediated or any new material weaknesses were assessed for the 2024 period, the Compensation Committee would assess the progress made by Management on remediation efforts to determine payout of this Company Objective.
 • Implementation of NetSuite MRP module on Media (20%): In 2024, the objective to implement the NetSuite MRP module on the media product line would result in a payout of 20% of each NEOs Target Award. If the NetSuite MRP module was not successfully implemented on the media product line during the 2024 period, no payout would be made to the NEOs with respect to the implementation of the NetSuite MRP module metric.
 (1) Adjusted EBITDA is a non-GAAP metric. A reconciliation of this metric is provided below.

 Non-GAAP metric reconciliation table
 Our Target Awards include the calculation of a non-GAAP financial measure which we believe provides useful information for evaluating business performance. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.
 Adjusted EBITDA reconciliation

 Year Ended December 31,

 2024

 GAAP Net loss from continuing operations
 $
 (11,387)

 ADJUSTMENTS:

 Interest expense, net

 Accretion of available-for-sale investments
 (476)

 Income tax benefit
 (38)

 Depreciation
 2,754

 Intangible asset amortization
 2,737

 EBITDA
 $
 (5,691)

 OTHER ADJUSTMENTS:

 Share-based compensation (non-cash)
 16,514

 Acquisition and divestiture costs
 1,260

 Loss on disposal of assets

 Change in fair value of investments
 4,074

 Other income
 (979)

 Inventory reserve costs

 ADJUSTED EBITDA
 $
 15,554

 % of Revenue
 %

 (1) Adjusted EBITDA excluded executive bonuses from GAAP operating expenses to determine target award percentage.
 Individual annual cash incentive targets
 For the fiscal year ended December 31, 2024, the Company established a Target Award for each NEO Company Objectives, which are set forth below:

 Name
 Target Award as % of Salary for the Fiscal Year Ended December 31, 2024
 Portion Tied to Company Objectives (%)

 Performance against 2024 company objectives
 The following table summarizes the performance of the Company against the Company Objectives for the fiscal year ended December 31, 2024:

 Company Objectives for the Fiscal Year Ended December 31, 2024

 Revenue target
 Revenues of $82 million met maximum payout threshold of 39%

 Adjusted EBITDA target
 Adjusted EBITDA margin of 19% of total revenues met maximum payout threshold of 39%

 Remediation of all material weaknesses
 The Company remediated all material weaknesses from 2023. However, incurred one new material weakness in 2024, resulting in payout of 10%.

 Implementation of NetSuite MRP module on Media
 The Company did not fully implement the NetSuite MRP module on Media product line, resulting in 0% payout of this objective.

 The Compensation Committee reviewed our achievement of the Company Objectives and determined that the Company achieved the Company Objectives at 88% of target levels. The Compensation Committee made this determination in consideration of revenues of $82 million, adjusted EBITDA, less executive bonus, of 19% of revenue, and the remediation of all previous material weaknesses of the Company. However, as the Company incurred one new material weakness during the year ended December 31, 2024, the Compensation Committee determined the NEOs would be awarded for 50% of the payout for the remediation of material weaknesses objective as outlined in the Company Objectives.
 Annual bonus incentive payments under the plan
 The table below shows the annual bonus incentive payments made to our NEOs under the Plan for the fiscal year ended December 31, 2024:

 Name(1)

 Target Award as % of Salary for the Fiscal Year Ended December 31, 2024
 2024 Company Objectives Results (%)
 2024 Bonus Payout ($)
 2024 Overall Achievement % of Target Award

 655,116

 172,260

 249,216

 148,004

 170,280

 (1) Garrie Richardson was not eligible for the payout of the annual bonus incentive due to the nature of his termination as defined within his employment agreement.
 Equity incentive compensation
 The Compensation Committee believes that equity incentives in the form of service vesting-based restricted stock awards and market-based restricted stock awards are effective instruments for long-term compensation. Equity incentives align individual and team performance with the achievement of the Company's strategic and financial goals, long-term value creation, and shareholders' interests. Restricted stock awards are impacted by all stock price changes, so the value to the executive officers is affected by both increases and decreases in stock price from the market price at the date of grant.
 For the fiscal year ended December 31, 2024, the Compensation Committee considered a number of factors in determining what, if any, equity incentive compensation to grant to the executive officers, including:
 • the performance of the Company during the fiscal year
 • the number of shares subject to, and exercise price of, outstanding options held by the executive officers
 • the number of restricted stock units held by the executive officers
 • the vesting schedule of the unvested equity awards held by the executive officers
 • the financial statement impact of any equity award
 • the amount and percentage of the total equity on a diluted basis held by the executive officers
 • the available shares under the Company's equity incentive plan

 The target split of the long-term equity incentive compensation awards made to our NEOs, based upon dollar value, is 50% market-based, and 50% service vesting-based restricted stock awards. We granted our NEOs these equity incentive instruments in 2024, 2023 and 2022 and we anticipate that we will continue to include these grants as part of our long-term incentive compensation program going forward for the reasons noted above.
 In March 2024, the Compensation Committee granted the following long-term incentive compensation awards to each of the NEOs of the Company. These awards are split based upon dollar value between service vesting-based restricted stock awards (50%) and target market-based restricted stock awards (50%) for all NEOs except the CEO, Mr. de Greef, who received a split based upon the dollar value between target market-based restricted stock awards (50%) and a target performance-based stock award (50%).

 Name
 Service-vesting based stock awards (#)
 Target Market-based Stock Units (#)
 Target Performance-based Stock Units (#)

 Roderick de Greef(1)

 —
 109,512
 109,512

 —

 —

 —

 Garrie Richardson(2)

 12,516
 25,032
 —

 —

 (1) As of the year ended December 31, 2024, the probability of attainment of the performance condition for Mr. de Greef's performance-based stock award increased to approximately 142% of shares granted (representing 155,178 shares).
 (2) Upon Mr. Richardson's termination on November 12, 2024, all service-vesting based shares, both vested and unvested, were accelerated. As of his termination date, Mr. Richardson's market-based awards vested at 200% according to the terms of his separation agreement.
 Service vesting-based equity awards granted in 2024 will vest one-quarter of the shares in one year with the remainder vesting quarterly over three years. Market-based restricted stock awards contain a market condition based on Total Shareholder Return ("TSR"). The TSR market condition measures the Company's performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group. Specifically, the market-based awards are earned at 200%, 150%, 125%, 100%, 50%, and 25% of target at the 80th, 70th, 60th, 50th, 40th, and 30th percentiles, respectively. Payout is capped at 200% and there is no payout if the Company's TSR is below the 30th percentile. Linear interpolation is used for achievement between the foregoing performance levels.
 For Mr. de Greef's performance-based award, the shares granted contain performance conditions related to adjusted EBITDA for fiscal year 2025 (before fiscal year 2025 bonuses). The performance-based award will be earned at 50% of target if such adjusted EBITDA is $19 million, 100% of target if such adjusted EBITDA is $21 million, and 200% of target if such adjusted EBITDA is $23 million. The payout is capped at 200%. No portion of the award is earned if such adjusted EBITDA is below $19 million. Achievement between tiers is linearly interpolated.
 2022 market-based stock units
 In February 2022, the Compensation Committee granted to the NEOs market-based restricted stock awards which contained a market condition based on TSR. The TSR market condition measured the Company's performance against a peer group. The market-based restricted stock awards were eligible to vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of our 20 company peer group disclosed in the Company's proxy statement filed in 2023. In early 2024, the Compensation Committee determined that the Company's TSR performance for fiscal 2022 through fiscal 2023 was at the 60th percentile, corresponding to a payout of 125% of the targeted shares of the 2022 TSRs.
 The Compensation Committee and, if applicable, the Board typically grant equity awards, including, if any, stock options, during their regularly scheduled meetings early in the fiscal year. However, the timing of this approval may be changed in the event of extraordinary circumstances, including in connection with mid-year promotions and new hires. The

 Compensation Committee and the Board do not take material nonpublic information into account when determining the timing and terms of equity awards, including options. The Compensation Committee and the Board do not time the release of material nonpublic information to affect the value of executive compensation.
 Other compensation
 All full-time employees, including the executive officers, are eligible to participate in the health benefits programs, including medical, dental and vision care coverage, disability and life insurance and the Company's 401(k) plan. Under the 401(k) plan, the Company matches 100% of the first 4% of eligible compensation contributed by employees. Additionally, the Company reimburses the Chief Executive Officer for travel expenses and additional tax gross up payments to cover travel costs between the corporate headquarters and their personal residence.
 Termination and change of control provisions
 We have entered into agreements with our NEOs that provide certain benefits if employment is terminated under certain circumstances, including under certain circumstances in connection with a change of control. We believe that these protections serve our retention objectives by permitting our NEOs to maintain continued focus and dedication to their responsibilities in order to maximize shareholder value, including in the event of a transaction that could result in a change of control of the Company. We believe that these protections promote the stability, continuity and impartiality of our executives in a change of control situation.
 Tax and accounting considerations
 We have not provided or agreed to provide any of the Company's executive officers or directors with a gross-up or other reimbursement for tax amounts they might pay pursuant to Section 4999 or Section 409A of the Internal Revenue Code of 1986, as amended (the "Code"). Sections 280G and 4999 of the Code provide that executive officers, directors who hold significant shareholder interests and certain other service providers could be subject to significant additional taxes if they receive payments or benefits in connection with a change in control of the Company that exceed certain limits, and that we or our successor could lose a deduction on the amounts subject to the additional tax. Section 409A also imposes additional significant taxes on the individual in the event that an employee, director or service provider receives "deferred compensation" that is not exempt from or does not meet the requirements of Section 409A.
 For the Company's financial statements, cash compensation, such as salary and bonus, is expensed and for income tax returns, cash compensation is generally deductible except as set forth below. For equity-based compensation, we expense the fair value of such grants over the requisite service period.
 Generally, Section 162(m) of the Code disallows a federal income tax deduction for public corporations of remuneration in excess of $1 million paid for any fiscal year to its chief executive officer, chief financial officer, and certain other current and former highly compensated employees that qualify as "covered employees" within the meaning of Section 162(m). The Compensation Committee believes that shareholder interests are best served if the Compensation Committee retains maximum flexibility to design executive compensation programs that meet stated business objectives. For these reasons, the Compensation Committee, while considering tax deductibility as a factor in determining executive compensation, may not limit such compensation to those levels that will be deductible.
 Incentive compensation clawback policy
 As required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (Dodd-Frank Act), we maintain a clawback policy, which requires that certain incentive compensation paid to any current or former executive officer, including our NEOs, will be subject to recoupment if (x) the incentive compensation was calculated based on financial statements that were required to be restated due to material noncompliance with financial reporting requirements, without regard to any fault or misconduct, and (y) that noncompliance resulted in overpayment of the incentive compensation within the three fiscal years preceding the fiscal year in which the restatement was required. Incentive compensation subject to the clawback policy consists of compensation that is granted, earned or vested based wholly or in part upon the attainment of a financial reporting measure (as defined in the rules implementing such requirement), including stock price and total shareholder return, on and after October 2, 2023.

 Compensation risk assessment
 The Compensation Committee not only considers and evaluates risks related to the Company's cash and equity-based compensation programs and practices, but also evaluates whether the Company's compensation plans encourage participants to take excessive risks that are reasonably likely to have a material adverse effect on the Company. Consistent with SEC disclosure requirements, the Compensation Committee has worked with management to assess compensation policies and practices for Company employees and has concluded that such policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company.
 Executive compensation tables
 Summary compensation table
 The following table summarizes the compensation earned during the fiscal years ended December 31, 2024, 2023, and 2022 by the NEOs, as such officers are determined in accordance with Regulation S-K.

 Name and Principal
Positions
(a)
 Year
(b)
 Salary
($)
(c)(1)
 Bonus
($) (d)
 Stock
Awards
($) (e)(2)
 Non-Equity
Incentive Plan
Compensation
($) (f)(3)
 All Other
Compensation
($) (g)
 Total
($)
(h)

 2024
 —
 5,571,874
 (4)
 655,116
 (5)
 74,765
 (6)
 7,046,205

 Chief Executive Officer and
 2023
 198,890
 (7)
 62,740
 (8)
 4,588,883
 —
 466,285
 5,316,798

 Chairman of the Board
 2022
 450,000
 —
 1,747,823
 185,850
 —
 2,383,673

 2024
 —
 1,111,511
 (9)
 172,260
 (10)
 14,723
 (11)
 1,733,494

 Executive Vice President and
 2023
 —
 897,488
 —
 13,200
 1,345,688

 Chief Scientific Officer
 2022
 419,750
 —
 1,155,834
 111,510
 12,200
 1,699,294

 2024
 —
 1,820,443
 (12)
 249,216
 (13)
 12,348
 (14)
 2,554,007

 Chief Financial Officer
 2023
 —
 1,212,021
 —
 13,200
 1,697,221

 2022
 375,000
 —
 1,245,968
 121,688
 12,200
 1,754,856

 Todd Berard - Chief Marketing Officer
 2024
 336,373
 (15)
 —
 630,860
 (16)
 148,004
 (17)
 12,258
 (18)
 1,127,495

 Garrie Richardson - Former Chief Revenue Officer
 2024
 317,479
 (19)
 —
 651,833
 (20)
 —
 417,976
 (21)
 1,387,288

 2024
 430,000
 —
 901,210
 (22)
 170,280
 (23)
 13,649
 (24)
 1,515,139

 Chief Quality and Operations
 2023
 382,000
 —
 727,677
 —
 13,200
 1,122,877

 Officer
 2022
 356,500
 —
 891,900
 84,252
 12,200
 1,344,852

 ________________________
 (1)Reflects base salary earned in each applicable period.
 (2)Represents the aggregate grant date fair value of restricted stock measured in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used in the valuation are consistent with the valuation methodologies specified in the notes to our consolidated financial statements included in our 2024 Annual Report. The fair value of the market-based restricted stock awards is estimated at the date of grant using the Monte Carlo Simulation model.
 (3)Represents the NEOs Cash Incentive Plan payouts, which are based on the performance of the Company relative to predetermined financial goals (Company Objectives) that closely align compensation with the Company's performance. The threshold, target, and maximum payout amounts for each NEOs Cash Incentive Plan payout opportunity for 2024 are shown in the table entitled Grants of Plan-Based Awards table below.
 (4)Represents fair value of 155,178 performance-based restricted stock and 109,512 market-based restricted stock granted on March 8, 2024. The performance-based restricted stock award granted March 8, 2024 will vest between 0% (0 shares) and 200% (219,024 shares) of the number of restricted shares granted (109,512 shares) to the recipient based on the achievement of certain financial metrics related to future performance through December 31, 2025. The Stock Awards amount reflects the increase in probability of attainment of Mr. de

 Greef's performance-based award to approximately 142% during the year ended December 31, 2024. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group.
 (5)Non-equity incentive cash bonus earned in 2024. The non-equity incentive bonus earned is determined based on achieving Company Objectives set by the Compensation Committee.
 (6)Represents travel expense reimbursement provided to Mr. de Greef for travel between his personal residence and corporate headquarters in Bothell, Washington. Per his employment agreement, Mr. de Greef is eligible for up to $75,000 in travel expense reimbursement each year.
 (7)The base salary reflected here is prorated for the period in which Mr. de Greef served as Chief Executive Officer. Mr. de Greef was appointed on October 19, 2023 to the position at a base salary of $744,450. The base salary presented reflects his service as CEO from his date of appointment through December 31, 2023. Mr. de Greef's salary also reflects his board retainer compensation for services performed as a Board Member from January 4, 2023 through October 18, 2023.
 (8)This bonus reflects Mr. de Greef's extraordinary award provided by the Board for extraordinary services as a director upon his appointment to Chief Executive Officer and Chairman on October 19, 2023.
 (9)Represents fair value of 25,470 service vesting-based restricted stock and 25,470 market-based restricted stock granted on March 8, 2024. The service vesting-based restricted stock award granted March 8, 2024 will vest 1/4 of the shares on March 8, 2025 with the remainder vesting quarterly over 3 years. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group.
 (10)Non-equity incentive cash bonus earned in 2024. The non-equity incentive bonus earned is determined based on achieving Company Objectives set by the Compensation Committee.
 (11)This amount represents the match paid by the Company on behalf of such individual into the Company 401(k) plan on 100% of the first 4% of eligible compensation contributed by such individual during the fiscal year 2024.
 (12)Represents fair value of 41,715 service vesting-based restricted stock and 41,715 market-based restricted stock granted on March 8, 2024. The service vesting-based restricted stock award granted March 8, 2024 will vest 1/4 of the shares on March 8, 2025 with the remainder vesting quarterly over 3 years. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group.
 (13)Non-equity incentive cash bonus earned in 2024. The non-equity incentive bonus earned is determined based on achieving Company Objectives set by the Compensation Committee.
 (14)This amount represents the match paid by the Company on behalf of such individual into the Company 401(k) plan on 100% of the first 4% of eligible compensation contributed by such individual during the fiscal year 2024.
 (15)The base salary presented here reflects a prorated value for Mr. Berard's salary increase that occurred on November 18, 2024. His salary increased from $332,000 to $370,000 as of that date.
 (16)Represents fair value of 14,456 service vesting-based restricted stock and 14,456 market-based restricted stock granted on March 8, 2024. The service vesting-based restricted stock award granted March 8, 2024 will vest 1/4 of the shares on March 8, 2025 with the remainder vesting quarterly over 3 years. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group.
 (17)Non-equity incentive cash bonus earned in 2024. The non-equity incentive bonus earned is determined based on achieving Company Objectives set by the Compensation Committee.
 (18)This amount represents the match paid by the Company on behalf of such individual into the Company 401(k) plan on 100% of the first 4% of eligible compensation contributed by such individual during the fiscal year 2024.
 (19)The base salary reflected here is prorated for the period in which Mr. Richardson served as Chief Revenue Officer. Mr. Richardson was terminated on November 12, 2024 upon the divestiture of SciSafe, Inc. He had a base salary of $367,500 effective January 1, 2024 through his termination date.
 (20)Represents fair value of 12,516 service vesting-based restricted stock and 25,032 market-based restricted stock granted on March 8, 2024. The service vesting-based restricted stock award granted March 8, 2024 was accelerated and fully vested as of Mr. Richardson's termination date of November 12, 2024. The market-based

 restricted stock awards were accelerated upon Mr. Richardson's termination and vested at 200% of the number of restricted shares granted according to the terms of his separation agreement.
 (21)Represents the severance paid out to Mr. Richardson upon his termination from the Company on November 12, 2024.
 (22)Represents fair value of 20,651 service vesting-based restricted stock and 20,651 market-based restricted stock granted on March 8, 2024. The service vesting-based restricted stock award granted March 8, 2024 will vest 1/4 of the shares on March 8, 2025 with the remainder vesting quarterly over 3 years. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of our 20 company peer group.
 (23)Non-equity incentive cash bonus earned in 2024. The non-equity incentive bonus earned is determined based on achieving Company Objectives set by the Compensation Committee.
 (24)This amount represents the match paid by the Company on behalf of such individual into the Company 401(k) plan on 100% of the first 4% of eligible compensation contributed by such individual during the fiscal year 2024.

 2024 Grants of plan-based awards
 The following table sets forth certain information regarding each grant of plan-based awards made to a NEO in the last completed fiscal year under any plan, including awards that subsequently have been forfeited.

 Estimated Future Payouts Under
Non-Equity Incentive Plan Awards
 Estimated Future Payouts Under
Equity Incentive Plan Awards
 All Other Stock
Awards: Number of
 Grant Date
Fair Value of

 Name (a)
 Award Type
 Grant Date
(b)
 Threshold
($) (c)
 Target
($) (d)
 Maximum
($) (e)
 Threshold
(#) (c)
 Target
(#) (d)
 Maximum
(#) (e)
 Shares of Stock
or Units (#) (e)
 Stock Awards
($) (f) (1)

 -
 148,890
 878,451
 —
 —
 —
 —
 —

 Performance-based RSUs(2)

 —
 109,512
 219,024
 —
 1,901,128

 —
 109,512
 219,024
 —
 2,877,975

 -
 39,150
 195,750
 230,985
 —
 —
 —
 —
 —

 —
 50,940
 —
 669,352

 —
 —
 —
 442,159

 -
 56,640
 283,200
 334,176
 —
 —
 —
 —
 —

 —
 83,430
 —
 1,096,270

 —
 —
 —
 724,172

 -
 33,637
 168,186
 198,460
 —
 —
 —
 —
 —

 —
 28,912
 —
 379,904

 —
 —
 —
 250,956

 -
 31,748
 158,740
 187,313
 —
 —
 —
 —
 —

 Market-based RSUs(3)

 —
 12,516
 25,032
 —
 434,556

 —
 —
 —
 12,516
 217,278

 -
 38,700
 193,500
 228,330
 —
 —
 —
 —
 —

 —
 41,302
 —
 542,708

 —
 —
 —
 358,501

 (1) Represents the aggregate grant date fair value of restricted stock measured in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used in the valuation are consistent with the valuation methodologies specified in the notes to our consolidated financial statements included in our 2024 Annual Report. The fair value of the market-based restricted stock awards is estimated at the date of grant using the Monte Carlo Simulation model.
 (2) As of the year ended December 31, 2024, the probability of attainment of the performance condition for Mr. de Greef's performance-based stock award increased to approximately 142% of shares granted (representing 155,178 shares).
 (3) In accordance with the terms of his separation agreement, Mr. Richardson's market-based award fully vested at 200% of the number of restricted shares granted and was not subject to the total shareholder return market condition during the period beginning on January 1, 2024 through December 31, 2025. The grant date fair value of his market-based restricted stock award presented here is instead based on the Company's stock price as of the grant date rather than the Monte Carlo Simulation model due to the adjusted vesting condition of his award.
 Discussion of summary compensation table and grants of plan-based awards table

 The Company's executive compensation policies and practices, pursuant to which the compensation set forth in the Summary Compensation Table and the Grants of Plan-Based Awards Table was paid or awarded, are described above under "Compensation Discussion and Analysis." The material terms of employment agreements and arrangements with the Company's NEOs are described below under the heading "Employment Arrangements." The material terms of the equity awards disclosed in the grants-of plan-based awards table are listed in the footnotes to the Summary Compensation Table, above.
 Outstanding equity awards at December 31, 2024
 The following table sets forth certain information regarding the outstanding stock option grants and stock awards held by the NEOs at December 31, 2024. Awards were made under both the 2013 Performance Incentive Plan and 2023 Omnibus Performance Incentive Plan. For the outstanding stock option grants and stock awards described below, vesting is conditioned on the NEO remaining in service to the Company through the applicable vesting date. Such awards may also be subject to accelerated vesting as described in "Potential Payments Upon Termination or Change in Control."

 OPTION AWARDS

 Name (a)
 Number of Securities Underlying Unexercised Options (#) Exercisable (b)
 Number of Securities Underlying Unexercised Options (#) Unexercisable (c)
 Equity Incentive Plan Awards:
Number of Securities Underlying Unexercised Unearned Options (#) (d)
 Option Exercise Price ($) (e)
 Option Expiration Date (f)

 100,000
 ––
 ––
 1.90
 4/13/2026(1)

 (1)This award is fully vested.

 UNVESTED SHARES

 Name (a)
 Grant Date (b)
 Number of shares or units of stock that have not vested (#) (c)
 Market value of shares or units of stock that have not vested (1) ($) (d)
 Equity incentive plan awards:
Number of unearned shares, units or other rights that have not vested (#) (e)
 Equity incentive plan awards:
Market or payout value of unearned shares, units or other rights that have not vested ($)(1)(f)

 10/19/2023
 296,142
 (2)
 7,687,846
 —
 —

 —
 —
 219,024
 (3)
 5,685,863

 2/8/2021
 (4)
 7,944
 —
 —

 2/24/2022
 6,572
 (5)
 170,609
 —
 —

 1/3/2023
 11,779
 (6)
 305,783
 20,940
 (7)
 543,602

 (8)
 661,201
 (9)
 661,201

 8/9/2021
 (10)
 9,216
 —
 —

 2/24/2022
 7,302
 (11)
 189,560
 —
 —

 1/3/2023
 19,292
 (12)
 500,820
 34,296
 (13)
 890,324

 (14)
 1,082,921
 (15)
 1,082,921

 2/8/2021
 (16)
 5,867
 —
 —

 2/24/2022
 4,381
 (17)
 113,731
 —
 —

 1/3/2023
 6,686
 (18)
 173,569
 11,885
 (19)
 308,535

 (20)
 375,278
 (21)
 375,278

 2/8/2021
 (22)
 6,750
 —
 —

 2/24/2022
 5,112
 (23)
 132,708
 —
 —

 1/3/2023
 9,551
 (24)
 247,944
 16,978
 (25)
 440,749

 (26)
 536,100
 (27)
 536,100

 (1)The dollar amounts shown in columns (d) and (f) are determined by multiplying the number of shares or units shown in column (c) or (e), as applicable, by $25.96, the closing price of our common stock on December 31, 2024.
 (2)Subject to the terms of the award agreement, the remaining 296,142 service vesting-based RSUs are scheduled to vest in 3 equal annual increments provided that Mr. de Greef continues to be employed with BioLife through the vesting dates.
 (3)The target number of 109,512 market-based RSUs is shown for Mr. de Greef's market-based award, in addition to the target number of 109,512 performance-based RSUs for Mr. de Greef's performance-based award. Between 0% and 200% of the target number of market-based RSUs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2024 and December 31, 2025. Between 0% and 200% of the target number of performance-based RSUs vest based on the Company's achievement of certain financial metrics.
 (4)306 unvested service vesting-based restricted stock awards ("RSAs") subject to this award vested on February 8, 2025.
 (5)1,314 RSAs subject to this award vested on February 24, 2025, and subject to the terms of the award agreement, the remaining 5,258 service vesting-based RSAs are scheduled to vest in 4 equal quarterly increments provided that Mr. Mathew continues to be employed with BioLife through the vesting dates.

 (6)1,309 RSAs subject to this award vested on January 3, 2025, and subject to the terms of the award agreement, the remaining 10,470 service vesting-based RSAs are scheduled to vest in 8 equal quarterly increments provided that Mr. Mathew continues to be employed with BioLife through the vesting dates.
 (7)The target number of 20,940 market-based RSAs is shown. Between 0% and 200% of the target number of market-based RSAs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2023 and December 31, 2024.
 (8)Subject to the terms of the award agreement, of the 25,470 unvested service vesting-based RSUs subject to this award will vest one year from the grant date, March 8, 2024 and, thereafter, will vest in 12 equal quarterly increments, provided that Mr. Mathew continues to be employed with BioLife through the vesting dates.
 (9)The target number of 25,470 market-based RSUs is shown. Between 0% and 200% of the target number of market-based RSUs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2024 and December 31, 2025.
 (10)355 unvested service vesting-based RSAs subject to this award vested on February 9, 2025.
 (11)1,460 RSAs subject to this award vested on February 24, 2025, and subject to the terms of the award agreement, the remaining 5,842 service vesting-based RSAs are scheduled to vest in 4 equal quarterly increments provided that Mr. Wichterman continues to be employed with BioLife through the vesting dates.
 (12)2,144 RSAs subject to this award vested on January 3, 2025, and subject to the terms of the award agreement, the remaining 17,148 service vesting-based RSAs are scheduled to vest in 8 equal quarterly increments provided that Mr. Wichterman continues to be employed with BioLife through the vesting dates.
 (13)The target number of 34,296 market-based RSAs is shown. Between 0% and 200% of the target number of market-based RSAs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2023 and December 31, 2024.
 (14)Subject to the terms of the award agreement, of the 41,715 unvested service vesting-based RSUs subject to this award will vest one year from the grant date, March 8, 2024 and, thereafter, will vest in 12 equal quarterly increments, provided that Mr. Wichterman continues to be employed with BioLife through the vesting dates.
 (15)The target number of 41,715 market-based RSUs is shown. Between 0% and 200% of the target number of market-based RSUs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2024 and December 31, 2025.
 (16)226 unvested service vesting-based RSAs subject to this award vested on February 8, 2025.
 (17)876 RSAs subject to this award vested on February 24, 2025, and subject to the terms of the award agreement, the remaining 3,505 service vesting-based RSAs are scheduled to vest in 4 equal quarterly increments provided that Mr. Berard continues to be employed with BioLife through the vesting dates.
 (18)743 RSAs subject to this award vested on January 3, 2025, and subject to the terms of the award agreement, the remaining 5,943 service vesting-based RSAs are scheduled to vest in 8 equal quarterly increments provided that Mr. Berard continues to be employed with BioLife through the vesting dates.
 (19)The target number of 11,885 market-based RSAs is shown. Between 0% and 200% of the target number of market-based RSAs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2023 and December 31, 2024.
 (20)Subject to the terms of the award agreement, of the 14,456 unvested service vesting-based RSUs subject to this award will vest one year from the grant date, March 8, 2024 and, thereafter, will vest in 12 equal quarterly increments, provided that Mr. Berard continues to be employed with BioLife through the vesting dates.
 (21)The target number of 14,456 market-based RSUs is shown. Between 0% and 200% of the target number of market-based RSUs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2024 and December 31, 2025.
 (22)260 unvested service vesting-based RSAs subject to this award vested on February 8, 2025.
 (23)1,023 RSAs subject to this award vested on February 24, 2025, and subject to the terms of the award agreement, the remaining 4,089 service vesting-based RSAs are scheduled to vest in 4 equal quarterly increments provided that Ms. Foster continues to be employed with BioLife through the vesting dates.
 (24)1,062 RSAs subject to this award vested on January 3, 2025, and subject to the terms of the award agreement, the remaining 8,489 service vesting-based RSAs are scheduled to vest in 8 equal quarterly increments provided that Ms. Foster continues to be employed with BioLife through the vesting dates.
 (25)The target number of 16,978 market-based RSAs is shown. Between 0% and 200% of the target number of market-based RSAs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2023 and December 31, 2024.
 (26)Subject to the terms of the award agreement, of the 20,651 unvested service vesting-based RSUs subject to this award will vest one year from the grant date, March 8, 2024 and, thereafter, will vest in 12 equal quarterly increments, provided that Ms. Foster continues to be employed with BioLife through the vesting dates.

 (27)The target number of 20,651 market-based RSUs is shown. Between 0% and 200% of the target number of market-based RSUs vest based on our TSR compared to our 20 company peer group over the relevant two-year performance period between January 1, 2024 and December 31, 2025.
 Option exercises and stock vested for the fiscal year ended December 31, 2024
 The following Option Exercises and Stock Vested table sets forth certain information regarding each exercise of stock options and each vesting of restricted stock during the last completed year for each of the NEOs on an aggregated basis.

 Option Awards
 Stock Awards

 Name (a)
 Number of
Shares
Acquired on
Exercise (#) (b)
 Value Realized on
Exercise ($)
(c)(1)
 Number of
Shares
Acquired on
Vesting (#) (d)
 Value Realized
on Vesting ($)
(e)(2)

 —
 —
 137,566
 2,977,635

 50,000
 1,066,876
 43,706
 783,860

 —
 —
 54,134
 970,911

 30,000
 523,400
 28,380
 509,664

 —
 —
 123,868
 2,919,942

 —
 —
 34,512
 619,264

 (1) Value realized is calculated based on the difference between the closing price of our common stock on the date of exercise and the exercise price of the stock option.
 (2) Value realized is calculated based on the closing price of our common stock on the date of vesting.
 Pension benefits
 The Company has no defined benefit plans or other supplemental retirement plans for the NEOs.
 Nonqualified deferred compensation
 The Company has no nonqualified defined contribution plans or other nonqualified deferred compensation plans for the NEOs.
 Employment agreements
 The terms and conditions of employment for each of our NEOs are set forth in written employment agreements, as amended from time to time ("employment agreements"). Each of the employment agreements with our NEOs sets forth the terms and conditions of such executive's employment with us and provides for severance and change in control payments and benefits, as described below.
 The Company entered into an employment agreement with Roderick de Greef, Chief Executive Officer and Chairman of the Board, effective December 1, 2020, as later amended, which has been superseded by an executive employment agreement dated October 19, 2023. Please see "Potential Payments Upon Termination or Upon Termination in Connection with a Change in Control" below for the severance benefits for which Mr. de Greef is eligible.
 The Company entered into an employment agreement with Troy Wichterman, Chief Financial Officer, effective November 4, 2021, as amended effective June 1, 2023 and August 15, 2023. Please see "Potential Payments Upon Termination or Upon Termination in Connection with a Change in Control" below for the severance benefits for which Mr. Wichterman is eligible.

 The Company entered into an employment agreement with Aby J. Mathew, Chief Scientific Officer and Executive Vice President, effective December 1, 2020, as amended effective January 1, 2023 and August 15, 2023. Please see "Potential Payments Upon Termination or Upon Termination in Connection with a Change in Control" below for the severance benefits for which Mr. Mathew is eligible.
 The Company entered into an employment agreement with Todd Berard, Chief Marketing Officer, effective January 1, 2018, as amended effective June 1, 2023 and August 15, 2023. Please see "Potential Payments Upon Termination or Upon Termination in Connection with a Change in Control" below for the severance benefits for which Mr. Berard is eligible.
 The Company entered into an employment agreement with Karen Foster, Chief Quality and Operations Officer, effective January 1, 2018, as amended effective June 1, 2023 and August 15, 2023. Please see "Potential Payments Upon Termination or Upon Termination in Connection with a Change in Control" below for the severance benefits for which Ms. Foster is eligible.
 Potential payments upon termination or change in control

 Executive Employment Agreements
 Pursuant to each NEO's employment agreement, upon termination of the NEO's employment by the Company without "cause" or the NEO's resignation for "good reason" (each as defined in each NEO's employment agreements), the NEO will receive the following severance payments: (i) a lump sum severance payment equal to 12 months' base salary, (ii) an amount equal to the cost of 12 months of medical insurance premiums at a monthly amount equal to the cost of COBRA coverage in effect as of the termination date, plus a tax gross-up with respect to such amount, and (iii) full vesting of all unvested equity awards.
 If the NEO's employment is terminated by the Company or the NEO resigns for "good reason" (except in the case of Mr. de Greef) upon, or within 12 months following, a "change in control" (as defined in each NEO's employment agreement) (the "change in control protection period"), the NEO will receive the following severance payments: (i) a lump sum severance payment equal to 12 months' (or, in the case of Mr. de Greef, 24 months') salary, (ii) 100% of any incentive cash and/or stock bonus opportunity for the year in which the Change in Control occurs, (iii) an amount equal to the cost of 12 months' (or, in the case of Mr. de Greef, 24 months') of medical insurance premiums at a monthly amount equal to the amount of COBRA coverage in effect as of the termination date, plus a tax gross-up with respect to such amount, and (iv) full vesting of all unvested equity awards.
 If the NEO's employment is terminated by the Company due to death or disability, the NEO will receive a prorated portion of any incentive bonus opportunity previously approved by the Board (assuming target level achievement) and full vesting of all unvested equity awards.
 For purposes of each of the NEO employment agreements, "cause" generally means any of the following has occurred: (i) any breach of the employment agreement by the executive; (ii) any failure to perform assigned job responsibilities that continues unremedied for a period of 10 days after written notice to the executive officer by the Company; (iii) the executive officer's malfeasance or misconduct in connection with the executive officer's duties under the employment agreement or any act or omission of the executive officer which is materially injurious to the financial condition or business reputation of the Company or any of its subsidiaries or affiliates, (iv) commission or conviction of a felony or misdemeanor or failure to contest prosecution for a felony or misdemeanor; (v) the Company's reasonable belief that the executive officer engaged in a violation of any statute, rule or regulation, any of which in the judgment of the Company is harmful to the business or to Company's reputation; (vi) the Company's reasonable belief that the executive officer engaged in unethical practices, dishonesty or disloyalty; or (vii) any reason that would constitute "cause" under the laws the State of Washington.
 For purposes of each of the NEO employment agreements, a "change in control" means (i) the consummation of a merger or consolidation of the Company with or into another entity, (ii) the dissolution, liquidation or winding up of the Company or (iii) the sale of all or substantially all of the Company's assets. The foregoing notwithstanding, a merger or consolidation of the Company shall not constitute a "Change in Control" if immediately after such merger or consolidation a majority of

 the voting power of the capital stock of the continuing or surviving entity, or any direct or indirect parent corporation of such continuing or surviving entity, will be owned by the persons who were the Company's stockholders immediately prior to such merger or consolidation in substantially the same proportions as their ownership of the voting power of the Company's capital stock immediately prior to such merger or consolidation.
 For purposes of each of the NEO employment agreements, "good reason" generally means the following: (i) the Company's material breach of the terms of the employment agreement or any other written agreement between the executive officer and Company; (ii) significant diminution in the nature or scope of the executive's authority, title, function or duties, (iii) a material reduction of the executive officer's salary or target bonus opportunity, other than as a result of a general salary reduction affecting substantially all Company employees; (iv) any failure by the Company to obtain the assumption of the employment agreement by any successor or assign of the Company; or, (v) a requirement that the executive officer be based at any office or location more than 50 miles from the executive officer's primary work location prior to the effective date of the employment agreement.
 Assuming the NEOs employment was terminated by the Company without cause or the NEOs resigned for good reason and such event took place on December 31, 2024, in each case, outside of the change in control protection period, each of the continuing NEOs would have been entitled to the payments and benefits shown in the table below.

 Payments and Benefits

 Name
 Base Salary ($)
 Accelerated Vesting of Equity Awards ($) (1)
 Health Insurance Under COBRA ($)
 Total ($)

 13,373,709
 36,676
 14,154,835

 2,350,341
 11,570
 2,796,911

 3,755,763
 22,714
 4,250,477

 370,000
 1,352,256
 36,676
 1,758,932

 430,000
 1,900,350
 25,491
 2,355,841

 (1) The dollar amounts shown are based on the intrinsic value of the stock options and restricted stock awards on December 31, 2024 calculated using $25.96, the closing price of our common stock on December 31, 2024, and assuming achievement for market-based or performance-based awards.

 Assuming the NEO's employment was terminated by the Company or the NEOs resigned for good reason upon or within 12 months following a change in control and such events took place on December 31, 2024, each of the continuing NEOs would have been entitled to the payments and benefits shown in the table below.

 Payments and Benefits

 Name
 Base Salary ($)
 2024 Annual Cash Incentive ($)
 Accelerated Vesting of Equity Awards ($) (2)
 Health Insurance Under COBRA ($)
 Total ($)

 1,488,900
 655,116
 13,373,709
 73,352
 15,591,077

 172,260
 2,350,341
 11,570
 2,969,171

 249,216
 3,755,763
 22,714
 4,499,693

 370,000
 148,004
 1,352,256
 36,676
 1,906,936

 430,000
 170,280
 1,900,350
 25,491
 2,526,121

 (1) The dollar amounts shown are based on the intrinsic value of the stock options and restricted stock awards on December 31, 2024 calculated using $25.96, the closing price of our common stock on December 31, 2024, and assuming achievement for market-based or performance-based awards.

 Assuming the NEO's employment was terminated by the Company due to death or disability and such event took place on December 31, 2024, each of the continuing NEOs would have been entitled to the payments and benefits shown in the table below.

 Payments and Benefits

 Name
 2024 Target Annual Cash Incentive ($)
 Accelerated Vesting of Equity Awards ($) (2)
 Total ($)

 655,116
 13,373,709
 14,028,825

 Aby J Mathew
 172,260
 2,350,341
 2,522,601

 249,216
 3,755,763
 4,004,979

 148,004
 1,352,256
 1,500,260

 170,280
 1,900,350
 2,070,630

 (1) The dollar amounts shown are based on the intrinsic value of the stock options and restricted stock awards on December 31, 2024 calculated using $25.96, the closing price of our common stock on December 31, 2024.

 Equity Incentive Plans and Forms of Award Agreements

 The 2023 Plan provides for full accelerated vesting of awards in the event a "change in control" (as defined in the 2023 Plan) occurs and the surviving entity or successor corporation in such change in control does not assume or substitute outstanding awards. The 2023 Plan further provides for "double-trigger" acceleration, meaning that in the event an award continues in effect or is assumed or substituted by the surviving entity or successor corporation in connection with a change in control, and an NEO's employment or service is terminated without "cause" (as defined in the 2023 Plan) upon or within 12 months following such change in control, all outstanding awards will accelerate and vest in full. The tables above disclose the value of such acceleration if the applicable event occurred on December 31, 2024.

 The award agreements under the 2013 Plan provide for "single-trigger" acceleration, meaning that in the event of a "change in control" (as defined in the 2013 Plan), all outstanding awards will accelerate and vest in full. The tables above disclose the value of such acceleration if the applicable event occurred on December 31, 2024.

 For purposes of the 2023 Plan, "cause" means, unless otherwise provided in an award agreement or employment or similar agreement entered into by and between the participant and the Company or any of its affiliates, termination of a participant's employment by the Company and its affiliates based on the employer's belief that any of the following has occurred: (a) the continued refusal or omission by the participant to perform any material duties required of such participant by the Company or any of its affiliates; (b) any act or omission by the participant involving malfeasance, misconduct, dishonesty or gross negligence in the performance of the participant's duties to, or material deviation from any of the policies or directives of, the Company or any of its affiliates; (c) the participant engaged in conduct that constitutes a breach of any statutory or common law duty of loyalty to the Company or any of its affiliates; (d) the participant engaged in a violation of any statute, rule, regulation or policy of the Company or any of its affiliates, any of which in the judgment of the Company is harmful to the business or reputation of the Company or any of its affiliates; (e) the participant's commission or conviction of a felony or misdemeanor (other than a misdemeanor traffic violation) or any crime involving moral turpitude, including a plea of guilty or failure to contest prosecution for a felony, misdemeanor or crime involving moral turpitude; (f) any reason that would constitute Cause under the laws of the State of Washington; or (g) the participant's breach of an employment or similar agreement entered into by and between the participant and the Company or any of its affiliates, including, without limitation, a breach of any restrictive covenants contained therein.

 For purposes of the 2013 Plan and the 2023 Plan, "change in control" generally means the occurrence of any of the following events: (a) the acquisition, directly or indirectly, in one transaction or a series of related transactions, by any person or group (within the meaning of Section 13(d)(3) of the Exchange Act) of the beneficial ownership of securities of the Company possessing more than 50% of the total combined voting power of all outstanding securities of the Company; (b) a merger or consolidation of the Company with any other entity, whether or not the Company is the surviving entity in such transaction; (c) the sale, transfer or other disposition (in one transaction or a series of related transactions) of all or

 substantially all of the consolidated assets of the Company; or (d) the approval by the stockholders of a plan or proposal for the liquidation or dissolution of the Company.
 CEO pay ratio
 Pursuant to a mandate of the Dodd-Frank Act, the SEC adopted a rule requiring that we annually disclose the ratio of our median employee's total annual compensation to the total annual compensation of our CEO, Roderick de Greef, who is also our principal executive officer (the "CEO Pay Ratio").
 We identified the median employee using total salary and wages earned, then subtracting executive bonuses earned in 2023 but paid in 2024, adding executive bonuses earned in 2024 but not paid until 2025, and adding the fair value of equity awards granted to the employee during 2024. Salary and wages were annualized for any employees hired during the most recent fiscal year. A total of 159 U.S. based employees who were employed by the Company on December 31, 2024, the last day of the Company's fiscal year, were included in the determination of this calculation (including all employees, whether employed on a full-time, part-time, seasonal or temporary basis).
 As illustrated in the table below, the Company's 2024 CEO Pay Ratio was approximately 58:1.

 Roderick de Greef (CEO) 2024 Compensation
 $
 7,046,205

 Median Employee 2024 Compensation
 $
 122,390

 CEO Pay Ratio
 58:1

 To determine the median employee, we included all individuals employed as of December 31, 2024. Compensation for the median employee was determined in the same manner as the total compensation reported for Mr. de Greef in the "Total" column of the Summary Compensation Table. The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules, based on the Company's internal records and the methodology described above. The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Accordingly, the pay ratio reported by other peer companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may use different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.
 Director compensation
 Our non-employee director compensation program is designed to attract, retain and reward qualified non-employee directors and align the financial interests of the non-employee directors with those of our stockholders. Pursuant to this program, each member of our Board who is not our employee received the cash and equity compensation for fiscal 2024 Board service described in the director compensation table below.
 Each of our non-employee directors, during the year ended December 31, 2024, were compensated with an annual retainer fee of $60,000. Committee chairpersons were compensated with additional annual retainers as follows:

 Annual Retainer

 Lead Director
 $
 40,000

 Audit Committee Chair
 $
 13,750

 Compensation Committee Chair
 $
 12,500

 Governance and Nominating Committee Chair
 $
 10,000

 The following table sets forth information regarding compensation earned by our non-employee directors for the year ended December 31, 2024.

 Name
 Annual Cash Retainer ($) (1)
 Board and Committee Chair Fees ($)
 Total Cash Compensation ($)

 Amy DuRoss
 52,500
 112,500

 —

 Joydeep Goswami(2)

 15,729
 75,729

 Tim Moore
 —

 Joseph Schick(2)

 35,000
 8,021
 43,021

 (1) Due to the timing of member resignations and appointments, the annual cash retainers vary depending on the respective period of time each director served.
 (2) Joseph Schick stepped down from his role as Director and Chair of the Audit Committee as of August 1, 2024. Joydeep Goswami assumed the role of Chair of the Audit Committee as of the same date. The annual retainer for the role of Audit Committee Chair was therefore prorated between the two for their respective months of service. The annual cash retainer for Mr. Schick was also prorated for his months of service.
 Roderick de Greef does not receive compensation for his services as Board Chairman.
 The Company's compensation practices for non-employee directors, as determined by the Compensation Committee and our independent compensation consultant, FW Cook, includes annual awards of restricted shares of our common stock. Equity compensation for non-employee directors was in the form of restricted stock units ("RSUs") and was based on a fixed value of $180,000 based on a share price of $15.98 as of January 2, 2024. These awards vest one year from the date of grant, provided such person is still a director on such vesting date.
 Director compensation table for the fiscal year ended December 31, 2024
 The following table sets forth a summary of the compensation the Company paid to its non-employee directors in the year ended December 31, 2024.

 Name
 Fees Earned or
Paid in Cash ($)
 Stock Awards
($) (1)(2)
 Total
Compensation
($)

 Amy DuRoss
 112,500
 308,043

 255,543

 Joydeep Goswami
 75,729
 271,272

 Tim Moore
 255,543

 Joseph Schick
 43,021
 238,564

 (1) Represents the grant date fair value of awards granted in 2024 calculated in accordance with the ASC Topic 718. The assumptions the Company used for calculating the grant date fair values are set forth in Note 1: Organization and significant accounting policies – Stock-based compensation."
 (2) The Company's non-employee directors were awarded 11,264 shares of RSUs as of January 2, 2024 based on a fixed value of $180,000. When the shares were granted and effective on March 8, 2024, the share price of the Company had increased to $17.36, therefore increasing the accounting grant date fair value of the stock awards as presented above.

 The following table presents the aggregate number of unvested RSUs held by directors as of December 31, 2024:

 Name
 Number of Unvested RSUs (#)

 Amy DuRoss
 11,264

 11,264

 Joydeep Goswami
 11,264

 Tim Moore
 11,264

 Joseph Schick(1)

 —

 (1) When Joseph Schick stepped down from his Director role on August 1, 2024, all 11,264 unvested stock units granted on March 8, 2024 were accelerated and vested as of the date of his separation. Because the grant date fair value of the award is included under the "Stock Awards" column in the director compensation table above, the intrinsic value of the shares on the vesting date (approximately $195,543) is not also included in the director compensation table.
 In early 2025, the Board adopted the Company's non-employee director compensation policy. Pursuant to the policy, each non-employee director will receive an annual cash retainer of $70,000 and each non-employee director who serves as a committee chair will receive an annual cash retainer as follows: Audit Committee Chair: $20,000; Compensation Committee Chair: $15,000; and Governance & Nominating Committee Chair: $10,000. The non-employee director, if any, who serves as the lead independent director will receive an annual cash retainer of $40,000. In lieu of cash, a non-employee director may elect to be paid, at the same time as a cash retainer would have been paid, shares of our common stock having an equivalent dollar value on the date on which such retainer would have been paid.
 Pursuant to the policy, each non-employee director will be granted, automatically, an annual award of RSUs having a nominal award value of $180,000 on the first trading day following January 1. The aggregate number of RSUs to be issued with respect to any awards of RSUs will equal (A) the award's intended dollar value of $180,000 divided by (B) the closing stock price of our common stock on the date of grant. The shares subject to such annual award will vest on the first annual anniversary of the grant date, provided that the non-employee director continues to serve as a director through such date. If a non-employee director ceases to serve as a non-employee director before the vesting date of an annual award due to the non-employee director's death or disability, or if there is a change in control prior to such vesting date, then the annual award will become fully vested as of the date of such death, disability or change in control, as applicable. The policy will become effective January 1, 2026.
 Compensation Committee interlocks and insider participation
 Ms. DuRoss, Mr. Schick, Ms. Ellingson, and Mr. Moore were the members of the Compensation Committee during the year ended December 31, 2024 (until Mr. Schick stepped down on August 1, 2024). No member of the Compensation Committee is a current or former employee of the Company or had any relationship with the Company requiring disclosure herein. No interlocking relationship exists between any member of the Board or the Compensation Committee and any member of the board or Compensation Committee of any other company and no such interlocking relationship has existed in the past.

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT RELATED STOCKHOLDER MATTERS
 The following table sets forth, as of March 27, 2025, certain information regarding the beneficial ownership of our common stock by (i) each stockholder known by the Company to be the beneficial owner of more than 5% of the outstanding shares of our common stock; (ii) each director of the Company; (iii) each named executive officer of the Company; and (iv) all of the Company's current directors and executive officers (including executive officers that are not named executive officers) as a group. This table is based upon information supplied by officers, directors, and principal stockholders and Schedule 13D(s) and Schedule 13G(s) filed with the SEC. There were 47.5 million outstanding shares as of March 27, 2025. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of March 27, 2025 (or subject to restricted stock awards that vest within 60 days of March 27, 2025) are considered outstanding and beneficially owned by the person holding such options (or restricted stock awards) for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as indicated by footnote, and subject to community property laws where applicable, we believe that the persons named in the table have sole voting and investment power with respect to all shares

 shown as beneficially owned by them. Note that RSUs subject to performance-based vesting conditions are treated differently. Unless otherwise indicated, the business address of each person listed is in care of 3303 Monte Villa Parkway, #310, Bothell, WA 98021.

 Name and Address of Beneficial Owner
 Common Stock
 Percentage of Class (1)

 Directors and Executive Officers

 Aby J. Mathew (Officer)(2)
 287,957
 *

 Karen Foster (Officer)(3)
 277,738
 *

 Roderick de Greef (Officer and Director)
 231,651
 *

 Troy Wichterman(Officer)(4)
 164,256
 *

 Todd Berard (Officer)(5)
 126,187
 *

 Rachel Ellingson (Director)
 49,825
 *

 Joydeep Goswami (Director)
 47,986
 *

 Tim Moore (Director)
 36,773
 *

 Amy DuRoss (Director)
 30,687
 *

 Tony Hunt (Director)
 6,876
 *

 Cathy Coste (Director)
 5,701
 *

 Total shares owned by Executive Officers and Directors (13 persons)
 1,343,259
 2.8
 %

 5% Stockholders

 Casdin Capital, LLC (6)
 8,707,165
 18.3
 %

 BlackRock, Inc.(7)
 5,424,116
 11.4
 %

 Invesco LTD (8)
 3,242,364
 6.8
 %

 The Vanguard Group (9)
 2,571,608
 5.4
 %

 Integrated Core Strategies (US) LLC (10)
 2,404,862
 5.1
 %

 *Less than 1%

 (1)Based on 47,548,431 shares of our common stock outstanding as of March 27, 2025.
 (2)Includes 2,623 shares of common stock to be issued pursuant to restricted stock awards within 60 days from March 27, 2025.
 (3)Includes options to purchase 100,000 shares of common stock issuable under stock options exercisable within 60 days from March 27, 2025 and 2,083 shares of common stock to be issued pursuant to restricted stock awards within 60 days from March 27, 2025.
 (4)Includes 3,604 shares of common stock to be issued pursuant to restricted stock awards within 60 days from March 27, 2025.
 (5)Includes 1,619 shares of common stock to be issued pursuant to restricted stock awards within 60 days from March 27, 2025.
 (6)Based on a Schedule 13D/A filed by Casdin Capital, LLC ("Casdin"), Casdin Partners Master Fund, L.P. (the "Fund"), Casdin Partners GP, LLC (the "GP") and Eli Casdin on October 24, 2023 reporting shared voting and dispositive power over 8,707,165 shares of common stock. Casdin is the investment manager to the Fund and GP is the general partner of the Fund. Eli Casdin is the managing member of Casdin and the GP. Pursuant to the Schedule 13D/A, Casdin, the GP and Eli Casdin may be deemed to be the beneficial owners of 8,707,165 shares of common stock, and the Fund may be deemed to be the beneficial owner of 8,557,165 shares of common stock. The business address of Casdin is 1350 Avenue of the Americas, Suite 2405, New York, New York 10019.
 (7)Based on a Schedule 13G/A filed by BlackRock, Inc. ("BlackRock") on January 23, 2024, reporting sole voting power over 5,379,424 shares of common stock and sole dispositive power over 5,424,116 shares of common stock. The business address of BlackRock is 50 Hudson Yards, New York, New York 10001.
 (8)Based on a Schedule 13G filed by Invesco Ltd. ("Invesco") on November 8, 2024, reporting sole voting power over 3,011,734 shares of common stock and sole dispositive power over 3,203,293 shares of common stock. The business address of Invesco is 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309.
 (9)Based on a Schedule 13G/A filed by The Vanguard Group ("Vanguard") on February 13, 2024, reporting shared voting power over 61,469 shares of common stock, sole dispositive power over 2,475,884 shares of common stock,

 and shared dispositive power over 95,724 shares of common stock. The business address of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355.
 (10)Based on a Schedule 13G/A filed Integrated Core Strategies (US) LLC ("Integrated"), Millennium Management LLC ("Millennium Management") and Millennium Group Management LLC ("Millenium Group") on January 24, 2024, reporting shared voting and dispositive power of Integrated over 2,404,862 shares of common stock. The shares reported as beneficially owned by Integrated may be deemed beneficially owned by Millennium Management, Millennium Group and Israel A. Englander and are held by entities subject to voting control and investment discretion by Millennium Management and/or other investment managers that may be controlled by Millennium Group (the managing member of Millennium Management) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group). The business address of Integrated is 399 Park Avenue, New York, New York 10022.
 Equity Compensation Plan Information
 The following table sets forth information as of December 31, 2024 relating to all our equity compensation plans:

 Plan category
 Number of
securities to
be issued upon
exercise
of outstanding
options or rights
(in thousands)
 Weighted Average
exercise price of
outstanding
options or rights
 Number of
granted restricted
stock awards
outstanding
(in thousands)
 Number of securities
remaining available
for future issuance under equity compensation plans
(in thousands)

 Equity compensation plans approved by stockholders: Second amended and restated 2013 performance incentive plan
 $
 2.67
 1,070

 Equity compensation plans approved by stockholders: 2023 Omnibus performance incentive plan
 —
 $
 —
 1,393
 2,577

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 Certain relationships and related transactions
 Other than as described under the headings "Executive Compensation" and "Director Compensation" in Item 11 of this Amendment No. 1, since January 1, 2024, there has not been, and there is not currently proposed, any transaction, arrangement or relationship or series of similar transactions, arrangements or relationships, in which:
 • we or our subsidiaries were or will be a participant;
 • the amount involved exceeded or exceeds $120,000; and
 • any of our directors, executive officers, beneficial owners of more than 5% of any class of our voting securities, any member of the immediate family of any such director or executive officer, or any person (other than a tenant or employee) sharing the household of any such director or executive officer had or will have a direct or indirect material interest.
 In accordance with our Audit Committee's charter, all related-party transactions required to be disclosed pursuant to the rules and regulations promulgated by the SEC are reviewed and approved by our Audit Committee.
 Director independence
 Our Board is responsible for determining the independence of our directors. For purposes of determining director independence, our Board has applied the definitions set forth in NASDAQ Rule 5605(a)(2) and the related rules of the

 SEC. Based upon its evaluation, our Board has affirmatively determined that the following directors meet the standards of independence: Ms. Coste, Ms. DuRoss, Ms. Ellingson, Mr. Goswami, Mr. Moore, and Mr. Hunt.

 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
 Independent Registered Public Accounting Firm Fees
 The following table sets forth the aggregate fees billed by our current independent auditors, Grant Thornton LLP ("Grant Thornton"), for professional services rendered in the fiscal years ended December 31, 2024 and 2023.

 2024
 2023

 Audit fees(1)

 $
 2,418,450
 $
 1,887,800

 Audit related fees(2)

 227,823
 18,550

 Total
 $
 2,646,273
 $
 1,906,350

 (1)Audit fees consist of professional services for the audit of our annual financial statements, review of financial statements included in our Forms 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagement for those fiscal years.
 (2)Audit-related fees consist of assurance and related services reasonably related to the performance of the audit or review of our financial statements that are not reported under the heading Audit fees above.
 Audit Committee Pre-Approval Policies and Procedures
 The Audit Committee must pre-approve all services to be performed for us by our independent auditors. Pre-approval is granted usually at regularly scheduled meetings of the Audit Committee. If unanticipated items arise between regularly scheduled meetings of the Audit Committee, the Audit Committee has delegated authority to the Chair of the Audit Committee to pre-approve services. The Audit Committee also may approve the additional unanticipated services by either convening a special meeting or acting by unanimous written consent. During the years ended December 31, 2024 and 2023, all services billed by Grant Thornton were pre-approved by the Audit Committee Chair in accordance with this policy.

 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 (a)The following documents are filed as part of this Annual Report on Form 10-K:
 (1)Financial Statements: Incorporated by reference to Item 15(a)(1) of the 2024 Annual Report
 (2)Financial Statement Schedules: Incorporated by reference to Item 15(a)(2) of the 2024 Annual Report.
 (b)Exhibits

 Exhibit Number
 Document

 2.1 *
 Agreement and Plan of Merger, dated as of March 19, 2021, by and among the Company, BLFS Merger Subsidiary, Inc., Global Cooling, Inc. and Albert Vierling and William Baumel, in their capacity as the representatives of the stockholders of Global Cooling, Inc. (included as Exhibit 2.1 to the current report on Form 8-K filed on March 25, 2021)

 2.2
 Agreement and Plan of Merger, dated as of August 9, 2021, by and among the Company, BLFS Merger Sub, Inc., Sexton Biotechnologies, Inc. and Fortis Advisors LLC, in their capacity as the representatives of the stockholders of Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 2.6 to Company's report on Form 10-K filed March 31, 2022)

 2.3***
 Stock Purchase Agreement, dated April 17, 2024, by and between BioLife Solutions, Inc. and GCI Holdings Company, LLC (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on April 23, 2024)

 2.4***
 Stock Purchase Agreement, dated November 12, 2024, by and between BioLife Solutions, Inc., SciSafe, Inc., and Subzero Purchaser Corp. (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on November 12, 2024)

 2.5***
 Stock Purchase Agreement, dated November 14, 2024, by and between BioLife Solutions, Inc. and Standex International Corporation (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on November 20, 2024)

 3.1
 Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 4.1 to the Registration Statement on Form S-8 filed on June 24, 2013)

 3.2
 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed on January 30, 2014)

 3.3
 Amended and Restated Bylaws of BioLife Solutions, Inc., effective November 12, 2024 (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on November 12, 2024)

 3.4
 Certificate of Designations, Preferences, and Rights of Series A Preferred Stock (included as Exhibit 3.1 to the current report on Form 8-K filed on July 6, 2017)

 4.1
 Description of the Company's Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.1**
 BioLife Solutions, Inc. 2023 Omnibus Incentive Plan (included as Exhibit 4.1 to the Registration Statement on Form S-8 for the fiscal year ended December 31, 2023 filed August 15, 2023)

 10.2**
 BioLife Solutions, Inc. Employee and Executive Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.3**
 BioLife Solutions, Inc. Director Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company's report on Form 10-K filed February 29, 2024)

 10.4**
 Second Amended and Restated 2013 Performance Incentive Plan (included as Appendix A to the Registrant's Definitive Proxy Statement filed on April 14, 2017)

 10.5**
 Amendment No. 1 to Second Amended and Restated 2013 Performance Incentive Plan (included as Exhibit 10.2 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed March 31, 2021)

 10.6**
 BioLife Solutions, Inc. Form of Non-Plan Stock Option Agreement (included as Exhibit 4.4 to the Registration Statement on Form S-8 filed on June 24, 2013)

 10.7**
 Form of Restricted Stock Purchase Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.4 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed on May 16, 2016)

 10.8**
 Form of Stock Option Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.5 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed on May 16, 2016)

 10.9**
 Amendment No. 2 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.5 of the Registrant's Registration Statement on Form S-8 filed on July 7, 2021)

 10.10**
 Amendment No. 3 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.6 of the Registrant's Registration Statement on Form S-8 filed on September 12, 2022)

 10.11
 Twelfth Amendment to the Lease, dated June 5, 2024, by and between the Company and ARE-SEATTLE No. 38, LLC (incorporated by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.12
 Lease Agreement dated October 1, 2019 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (incorporated by reference to Exhibit 10.26 to Company's report on Form 10-K filed March 31, 2022)

 10.13
 Second Amendment to the Lease, dated November 5, 2024 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (incorporated by reference to Exhibit 10.13 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.14
 Lease Agreement dated September 13, 2022 for facility space 19510 144th Avenue NE, Suite A-1, Woodinville, WA 98072 (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.15*
 Loan and Security Agreement, dated September 20, 2022, between BioLife Solutions, Inc. and Silicon Valley Bank (incorporated by reference to Exhibit 10.1 to the Company's report on Form 10-Q filed November 9, 2022)

 10.16*
 Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, between BioLife Solutions, Inc. and First Citizens Bank and Trust Company (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed February 29, 2024)

 10.17
 Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., Global Cooling, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on April 23, 2024)

 10.18
 Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed on November 12, 2024)

 10.19**
 Executive Employment Agreement, dated October 19, 2023, by and between the Company and Roderick de Greef (incorporated by reference to Exhibit 10.2 to the Company's report on Form 8-K filed October 23, 2023)

 10.20**
 Separation, Release of Claims and Consulting Agreement, dated October 19, 2023, by and between the Company and Michael Rice (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed October 23, 2023)

 10.21**
 Amended Employment Agreement dated January 5, 2023 between the Company and Aby Mathew (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.22**
 Amended Employment Agreement dated June 1, 2023 between the Company and Todd Berard (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.23**
 Amended Employment Agreement dated June 1, 2023 between the Company and Karen Foster (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.24**
 Amended Employment Agreement dated June 1, 2023 between the Company and Sarah Aebersold (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.25**
 Amended Employment Agreement dated June 1, 2023 between the Company and Troy Wichterman (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 10.26**
 Board of Directors Services Agreement entered into May 4, 2015 by and between the Company and Other Non-Employee Directors (included as Exhibit 10.3 to the Current Report on Form 8-K filed on May 5, 2015)

 10.27**
 Form of Amendment to Employment Terms (incorporated by reference to Exhibit 10.1 to the Company's report on Form 8-K filed August 16, 2023)

 19.1
 Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 21.1
 List of the Company's Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 23.1
 Consent of Grant Thornton USA, LLP (incorporated by reference to Exhibit 23.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 31.1
 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 31.2
 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 31.3
 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

 31.4
 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

 32.1
 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 32.2
 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 97.1
 BioLife Solutions, Inc. Incentive-based compensation recovery policy (incorporated by reference to Exhibit 97.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 *
 Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.

 **
 Management contract or compensatory plan or arrangement.

 ***
 Certain potions portions of this exhibit have been redacted pursuant to Item 601(a)(5) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.

 The exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

 (c)Excluded financial statements:
 None.

 SIGNATURES
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 Date:
 April 8, 2025

 BIOLIFE SOLUTIONS, INC.

 /s/ RODERICK DE GREEF

 Chief Executive Officer (principal executive officer) and Chairman of the Board of Directors